Vital Science Transistor (https://transistor.fm) https://feeds.transistor.fm/vital-science Life science is complicated, but its mission is simple – to create a safer, healthier future. This podcast tells the stories behind the science from the perspective of patients, scientists, employees, and advocates that have felt its impact. © 2025 Charles River 010559c0-96ae-5b4c-a7c6-50d119b844be no This is Vital Science™ en Wed, 23 Jul 2025 10:36:53 -0400 Tue, 02 Dec 2025 15:23:29 -0500 http://www.criver.com/vitalsciencepodcast https://img.transistor.fm/7qfFFmsF-WMWpas9SxMImc5CVv9DKzTYPhBc_YvXXZo/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzM1NTkvMTU2OTkz/Njc0My1hcnR3b3Jr/LmpwZw.jpg Vital Science http://www.criver.com/vitalsciencepodcast episodic Charles River Life science is complicated, but its mission is simple – to create a safer, healthier future. This podcast tells the stories behind the science from the perspective of patients, scientists, employees, and advocates that have felt its impact. Life science is complicated, but its mission is simple – to create a safer, healthier future. life sciences, biotech, pharma, CRO, drug development Vital Science No No FOXG1: A Mom’s Mission 5 5 10 10 FOXG1: A Mom’s Mission full 6756d117-2465-4eb2-93bc-be05764ceb65 https://share.transistor.fm/s/4cae94ce Being the parent of a child with an ultra-rare disease can be a daunting challenge.

Nasha Fitter is no different. Her daughter Amara is nonverbal and suffers from epileptic seizures, two of the common symptoms associated with her eventual diagnosis of an ultra-rare neurodevelopmental disorder known as FOXG1 Syndrome. Motivated by her desire to learn more about this condition, she co-founded the FOXG1 Research Foundation (FRF) with her fellow peers.

Through all the challenges they’ve faced, Nasha and FRF are set to conduct critical research in the hopes of developing a treatment for not just this condition, but other ultra-rare diseases primarily affecting children to eventually give them “the life they deserve.”

Join us as we conclude season five where Nasha discusses the origins of FRF, how Amara’s life has been shaped by her diagnosis, how collaboration has helped advance the Foundation’s mission, and what you can do to support their ultimate goals.

Show Notes

]]> Being the parent of a child with an ultra-rare disease can be a daunting challenge.

Nasha Fitter is no different. Her daughter Amara is nonverbal and suffers from epileptic seizures, two of the common symptoms associated with her eventual diagnosis of an ultra-rare neurodevelopmental disorder known as FOXG1 Syndrome. Motivated by her desire to learn more about this condition, she co-founded the FOXG1 Research Foundation (FRF) with her fellow peers.

Through all the challenges they’ve faced, Nasha and FRF are set to conduct critical research in the hopes of developing a treatment for not just this condition, but other ultra-rare diseases primarily affecting children to eventually give them “the life they deserve.”

Join us as we conclude season five where Nasha discusses the origins of FRF, how Amara’s life has been shaped by her diagnosis, how collaboration has helped advance the Foundation’s mission, and what you can do to support their ultimate goals.

Show Notes

]]> Tue, 16 Jul 2024 04:00:00 -0400 Charles River Charles River 1900 Being the parent of a child with an ultra-rare disease can be a daunting challenge.

Nasha Fitter is no different. Her daughter Amara is nonverbal and suffers from epileptic seizures, two of the common symptoms associated with her eventual diagnosis of an ultra-rare neurodevelopmental disorder known as FOXG1 Syndrome. Motivated by her desire to learn more about this condition, she co-founded the FOXG1 Research Foundation (FRF) with her fellow peers.

Through all the challenges they’ve faced, Nasha and FRF are set to conduct critical research in the hopes of developing a treatment for not just this condition, but other ultra-rare diseases primarily affecting children to eventually give them “the life they deserve.”

Join us as we conclude season five where Nasha discusses the origins of FRF, how Amara’s life has been shaped by her diagnosis, how collaboration has helped advance the Foundation’s mission, and what you can do to support their ultimate goals.

Show Notes

]]> FOXG1, epileptic seizures, epilepsy, neurodevelopmental disorder, Nasha Fitter, rare disease, ultra-rare disease, White House Rare Disease Forum, life sciences, biotech, pharma, CRO, drug development No Cure EB: Healing the Wounds 5 5 9 9 Cure EB: Healing the Wounds full f1bad906-4be7-462c-beb9-a9920d66dd20 https://share.transistor.fm/s/5ef53f48 Imagine giving birth to a baby girl and noticing pieces of skin missing from her body almost immediately.  

For Sharmila Nikapota, this was the case with her firstborn, Sohana. Genetic testing revealed that she was one of the over 500,000 people globally suffering from Epidermolysis Bullosa (EB), a “constantly painful and debilitating” skin condition where minimal contact can lead to blisters, wounds, tissue damage, eating difficulties, and eye injuries, among other symptoms. After seeking answers for her daughter’s prognosis and not getting any, Sharmila started Cure EB to educate people and eventually discover ways to manage this painful condition. With the UK approving a first-of-its-kind topical treatment for EB, she hopes it’s the first of many that can give patients like her daughter a better quality of life.

Join Sharmila as she discusses how Sohana’s experience with EB has shaped her personality, the origin and mission of Cure EB, the challenges of managing Sohana’s condition, and what you can do to further Cure EB’s ultimate goals.

Show Notes 

Cure EB - Accelerating Research to End Painful Skin
Birch Bark Extract: A Review in Epidermis Bullosa
Charles River | Cell and Gene Therapy
Charles River | Rare Disease
Eureka Blog | Living Rare
Krystal Biotech Touts Topical Gene Therapy Uptake

]]> Imagine giving birth to a baby girl and noticing pieces of skin missing from her body almost immediately.  

For Sharmila Nikapota, this was the case with her firstborn, Sohana. Genetic testing revealed that she was one of the over 500,000 people globally suffering from Epidermolysis Bullosa (EB), a “constantly painful and debilitating” skin condition where minimal contact can lead to blisters, wounds, tissue damage, eating difficulties, and eye injuries, among other symptoms. After seeking answers for her daughter’s prognosis and not getting any, Sharmila started Cure EB to educate people and eventually discover ways to manage this painful condition. With the UK approving a first-of-its-kind topical treatment for EB, she hopes it’s the first of many that can give patients like her daughter a better quality of life.

Join Sharmila as she discusses how Sohana’s experience with EB has shaped her personality, the origin and mission of Cure EB, the challenges of managing Sohana’s condition, and what you can do to further Cure EB’s ultimate goals.

Show Notes 

Cure EB - Accelerating Research to End Painful Skin
Birch Bark Extract: A Review in Epidermis Bullosa
Charles River | Cell and Gene Therapy
Charles River | Rare Disease
Eureka Blog | Living Rare
Krystal Biotech Touts Topical Gene Therapy Uptake

]]> Tue, 18 Jun 2024 08:31:06 -0400 Charles River Charles River 2484 Imagine giving birth to a baby girl and noticing pieces of skin missing from her body almost immediately.  

For Sharmila Nikapota, this was the case with her firstborn, Sohana. Genetic testing revealed that she was one of the over 500,000 people globally suffering from Epidermolysis Bullosa (EB), a “constantly painful and debilitating” skin condition where minimal contact can lead to blisters, wounds, tissue damage, eating difficulties, and eye injuries, among other symptoms. After seeking answers for her daughter’s prognosis and not getting any, Sharmila started Cure EB to educate people and eventually discover ways to manage this painful condition. With the UK approving a first-of-its-kind topical treatment for EB, she hopes it’s the first of many that can give patients like her daughter a better quality of life.

Join Sharmila as she discusses how Sohana’s experience with EB has shaped her personality, the origin and mission of Cure EB, the challenges of managing Sohana’s condition, and what you can do to further Cure EB’s ultimate goals.

Show Notes 

Cure EB - Accelerating Research to End Painful Skin
Birch Bark Extract: A Review in Epidermis Bullosa
Charles River | Cell and Gene Therapy
Charles River | Rare Disease
Eureka Blog | Living Rare
Krystal Biotech Touts Topical Gene Therapy Uptake

]]> Cure EB, Epidermolysis Bullosa, B-VEC, Sharmila Nikapota, Sohana Nikapota, rare disease, life sciences, biotech, pharma, CRO, drug development No Clear Scientific: Combatting Drug Overdose from Methamphetamine, Fentanyl, and Polydrug 5 5 8 8 Clear Scientific: Combatting Drug Overdose from Methamphetamine, Fentanyl, and Polydrug full ad14fff8-e860-46c9-b280-702353dd34a1 https://share.transistor.fm/s/fd9398ec Stimulant use in the United States has exploded into a nationwide crisis, as deaths and emergency room visits resulting from methamphetamine and cocaine use are rising at an alarming rate.

The overall substance abuse disorder crisis is further exacerbated by the high level of fentanyl use, which has long been referred to as an opioid epidemic, and the increasing use of more than substance at once. One fundamental limitation on the ability to respond to the crisis is that, to date, there is no FDA-approved therapeutic to treat overdose from stimulants like methamphetamine and cocaine, or polydrug. Users who want to get clean and rid themselves of methamphetamine, cocaine, and/or fentanyl often find it difficult, essentially “chaining” themselves into a cycle of use that’s mostly impossible to break.

First responders and emergency department physicians lack sufficient tools to treat overdose. But what if there was a treatment that could eliminate toxins and restore normal bodily function within minutes? That’s the aim of Clear Scientific, a small biotech in Cambridge, MA that’s currently testing a treatment (CS-1103) using small molecules to “eat” toxins and deactivate their harmful effects almost instantly. With Phase I of a first-in-human (FIH) clinical trial ongoing, this revolutionary therapeutic is offering hope to those suffering from drug misuse and addiction a “chance to get better.”

Join us as Mitch Zakin, Co-founder and Executive Vice President of Innovation, and Winston Henderson, Co-founder and General Counsel, discuss their therapeutic approach, offer an update on their progress with CS-1103, how collaboration has enhanced their development, and how they hope it will eventually impact this epidemic.

Show Notes  


Clear Scientific 

World Congress: Drug Modality Game Changers 

Clear Scientific to Start Phase 1 Trial for Stimulant Antidote 

Charles River | IND-Enabling Studies 

Charles River | Small Molecule 

]]> Stimulant use in the United States has exploded into a nationwide crisis, as deaths and emergency room visits resulting from methamphetamine and cocaine use are rising at an alarming rate.

The overall substance abuse disorder crisis is further exacerbated by the high level of fentanyl use, which has long been referred to as an opioid epidemic, and the increasing use of more than substance at once. One fundamental limitation on the ability to respond to the crisis is that, to date, there is no FDA-approved therapeutic to treat overdose from stimulants like methamphetamine and cocaine, or polydrug. Users who want to get clean and rid themselves of methamphetamine, cocaine, and/or fentanyl often find it difficult, essentially “chaining” themselves into a cycle of use that’s mostly impossible to break.

First responders and emergency department physicians lack sufficient tools to treat overdose. But what if there was a treatment that could eliminate toxins and restore normal bodily function within minutes? That’s the aim of Clear Scientific, a small biotech in Cambridge, MA that’s currently testing a treatment (CS-1103) using small molecules to “eat” toxins and deactivate their harmful effects almost instantly. With Phase I of a first-in-human (FIH) clinical trial ongoing, this revolutionary therapeutic is offering hope to those suffering from drug misuse and addiction a “chance to get better.”

Join us as Mitch Zakin, Co-founder and Executive Vice President of Innovation, and Winston Henderson, Co-founder and General Counsel, discuss their therapeutic approach, offer an update on their progress with CS-1103, how collaboration has enhanced their development, and how they hope it will eventually impact this epidemic.

Show Notes  


Clear Scientific 

World Congress: Drug Modality Game Changers 

Clear Scientific to Start Phase 1 Trial for Stimulant Antidote 

Charles River | IND-Enabling Studies 

Charles River | Small Molecule 

]]> Tue, 21 May 2024 04:00:00 -0400 Charles River Charles River 1613 Stimulant use in the United States has exploded into a nationwide crisis, as deaths and emergency room visits resulting from methamphetamine and cocaine use are rising at an alarming rate.

The overall substance abuse disorder crisis is further exacerbated by the high level of fentanyl use, which has long been referred to as an opioid epidemic, and the increasing use of more than substance at once. One fundamental limitation on the ability to respond to the crisis is that, to date, there is no FDA-approved therapeutic to treat overdose from stimulants like methamphetamine and cocaine, or polydrug. Users who want to get clean and rid themselves of methamphetamine, cocaine, and/or fentanyl often find it difficult, essentially “chaining” themselves into a cycle of use that’s mostly impossible to break.

First responders and emergency department physicians lack sufficient tools to treat overdose. But what if there was a treatment that could eliminate toxins and restore normal bodily function within minutes? That’s the aim of Clear Scientific, a small biotech in Cambridge, MA that’s currently testing a treatment (CS-1103) using small molecules to “eat” toxins and deactivate their harmful effects almost instantly. With Phase I of a first-in-human (FIH) clinical trial ongoing, this revolutionary therapeutic is offering hope to those suffering from drug misuse and addiction a “chance to get better.”

Join us as Mitch Zakin, Co-founder and Executive Vice President of Innovation, and Winston Henderson, Co-founder and General Counsel, discuss their therapeutic approach, offer an update on their progress with CS-1103, how collaboration has enhanced their development, and how they hope it will eventually impact this epidemic.

Show Notes  


Clear Scientific 

World Congress: Drug Modality Game Changers 

Clear Scientific to Start Phase 1 Trial for Stimulant Antidote 

Charles River | IND-Enabling Studies 

Charles River | Small Molecule 

]]> overdose, drug addiction, drug abuse, fentanyl, methamphetamine, meth, cocaine, opioid, detox, life sciences, biotech, pharma, CRO, drug development No Mission Therapeutics: Inhibiting DUBs to Halt Diseases 5 5 7 7 Mission Therapeutics: Inhibiting DUBs to Halt Diseases full 1efcac53-f380-41bf-b733-26c4988b716a https://share.transistor.fm/s/08e72b94 At Mission Therapeutics, Sarah Almond serves as their Head of Pharmacology, but she wears many hats to help develop potential treatments for neurodegenerative conditions.    

  

Their main area of focus centers around research into deubiquitinating enzymes (DUBs), which may impact neurodegeneration. By studying DUBs, Sarah and her team have been able to generate highly targeted and potent molecules that contribute to developing safe and effective therapeutics. In fact, one of these compounds (MTX325) is currently enrolled in a clinical trial to test its safety and pharmacokinetics ahead of effectiveness in treating Parkinson’s disease, a neurodegenerative condition impacting the central nervous system. With the first patient dosing scheduled for later this year, they are hopeful it could be a gamechanger for treating these debilitating conditions.    

  

Join Sarah as we discuss Mission Therapeutics, the science behind DUBs, how collaboration with a CRO advanced their research, and what her thoughts are on the future of drug discovery and development for neurodegenerative conditions, among others.

Show Notes

]]> At Mission Therapeutics, Sarah Almond serves as their Head of Pharmacology, but she wears many hats to help develop potential treatments for neurodegenerative conditions.    

  

Their main area of focus centers around research into deubiquitinating enzymes (DUBs), which may impact neurodegeneration. By studying DUBs, Sarah and her team have been able to generate highly targeted and potent molecules that contribute to developing safe and effective therapeutics. In fact, one of these compounds (MTX325) is currently enrolled in a clinical trial to test its safety and pharmacokinetics ahead of effectiveness in treating Parkinson’s disease, a neurodegenerative condition impacting the central nervous system. With the first patient dosing scheduled for later this year, they are hopeful it could be a gamechanger for treating these debilitating conditions.    

  

Join Sarah as we discuss Mission Therapeutics, the science behind DUBs, how collaboration with a CRO advanced their research, and what her thoughts are on the future of drug discovery and development for neurodegenerative conditions, among others.

Show Notes

]]> Tue, 16 Apr 2024 04:00:00 -0400 Charles River Charles River 1042 At Mission Therapeutics, Sarah Almond serves as their Head of Pharmacology, but she wears many hats to help develop potential treatments for neurodegenerative conditions.    

  

Their main area of focus centers around research into deubiquitinating enzymes (DUBs), which may impact neurodegeneration. By studying DUBs, Sarah and her team have been able to generate highly targeted and potent molecules that contribute to developing safe and effective therapeutics. In fact, one of these compounds (MTX325) is currently enrolled in a clinical trial to test its safety and pharmacokinetics ahead of effectiveness in treating Parkinson’s disease, a neurodegenerative condition impacting the central nervous system. With the first patient dosing scheduled for later this year, they are hopeful it could be a gamechanger for treating these debilitating conditions.    

  

Join Sarah as we discuss Mission Therapeutics, the science behind DUBs, how collaboration with a CRO advanced their research, and what her thoughts are on the future of drug discovery and development for neurodegenerative conditions, among others.

Show Notes

]]> DUBs, neurodegeneration, MTX325, Parkinson's, Mission Therapeutics, life sciences, biotech, pharma, CRO, drug development No Cure Rare Disease: Continuing a Legacy 5 5 6 6 Cure Rare Disease: Continuing a Legacy full 263d1e1d-4ed4-4ba2-a033-7494d2861c99 https://share.transistor.fm/s/56a9f83c When he founded Cure Rare Disease in 2018, Rich Horgan was primarily focused on finding a treatment for his younger brother Terry, who had an ultra-rare form of Duchenne Muscular Dystrophy (DMD).  

 

Suffering from a disease that has no cure, Terry served as a “selfless, brave, and courageous” figure that Rich continues to draw inspiration from when seeking new, innovative solutions to treat this progressive, neurodegenerative condition.  

 

Join us for this interview as Rich discusses the origins of Cure Rare Disease, Terry’s ongoing legacy, the collaborative effort it takes to advance the drug development journey, the important role of the patient voice when developing treatments, and the future of rare disease research. 

Show Notes 

  

]]> When he founded Cure Rare Disease in 2018, Rich Horgan was primarily focused on finding a treatment for his younger brother Terry, who had an ultra-rare form of Duchenne Muscular Dystrophy (DMD).  

 

Suffering from a disease that has no cure, Terry served as a “selfless, brave, and courageous” figure that Rich continues to draw inspiration from when seeking new, innovative solutions to treat this progressive, neurodegenerative condition.  

 

Join us for this interview as Rich discusses the origins of Cure Rare Disease, Terry’s ongoing legacy, the collaborative effort it takes to advance the drug development journey, the important role of the patient voice when developing treatments, and the future of rare disease research. 

Show Notes 

  

]]> Tue, 20 Feb 2024 13:21:39 -0500 Charles River Charles River 2157 When he founded Cure Rare Disease in 2018, Rich Horgan was primarily focused on finding a treatment for his younger brother Terry, who had an ultra-rare form of Duchenne Muscular Dystrophy (DMD).  

 

Suffering from a disease that has no cure, Terry served as a “selfless, brave, and courageous” figure that Rich continues to draw inspiration from when seeking new, innovative solutions to treat this progressive, neurodegenerative condition.  

 

Join us for this interview as Rich discusses the origins of Cure Rare Disease, Terry’s ongoing legacy, the collaborative effort it takes to advance the drug development journey, the important role of the patient voice when developing treatments, and the future of rare disease research. 

Show Notes 

  

]]> gene therapy, rare disease, Duchenne Muscular Dystrophy, DMD, therapeutic, life sciences, biotech, pharma, CRO, drug development No H-Guard: Improving Physical and Mental Health 5 5 5 5 H-Guard: Improving Physical and Mental Health full 4f304a9b-c249-4bf6-b3a2-908a9cb3d9dc https://share.transistor.fm/s/ccd7ba07 For the 850 million people around the world suffering from chronic kidney disease, the grind of dialysis treatment can wear them down in more ways than one.   

 

Dr. Andy Herbert, co-founder of Invizius, is out to change that. This five-year-old company started from humble beginnings and is currently developing H-Guard® Priming Solution, which increases the effectiveness of dialysis while negating, or eliminating, its potentially dangerous side effects. It will be used in an upcoming first-in-human clinical trial and has the potential to improve patients’ quality of life – both physically and mentally.  

 

Join Dr. Herbert as we discuss the origins of Invizius, how H-Guard works, why dialysis can take a toll on mental health, and how working with a strategic partner has helped Invizius progress this treatment.

Show Notes  

 
Invizius 

Charles River's Nonclinical Support Helps Invizius Secure MHRA Approval for First-in-Human Trial of H-Guard® Hemodialysis Solution 

Renal Disorders | Charles River 

Preclinical CRO Services for Safety Assessment 

Inflammation | Charles River

]]> For the 850 million people around the world suffering from chronic kidney disease, the grind of dialysis treatment can wear them down in more ways than one.   

 

Dr. Andy Herbert, co-founder of Invizius, is out to change that. This five-year-old company started from humble beginnings and is currently developing H-Guard® Priming Solution, which increases the effectiveness of dialysis while negating, or eliminating, its potentially dangerous side effects. It will be used in an upcoming first-in-human clinical trial and has the potential to improve patients’ quality of life – both physically and mentally.  

 

Join Dr. Herbert as we discuss the origins of Invizius, how H-Guard works, why dialysis can take a toll on mental health, and how working with a strategic partner has helped Invizius progress this treatment.

Show Notes  

 
Invizius 

Charles River's Nonclinical Support Helps Invizius Secure MHRA Approval for First-in-Human Trial of H-Guard® Hemodialysis Solution 

Renal Disorders | Charles River 

Preclinical CRO Services for Safety Assessment 

Inflammation | Charles River

]]> Tue, 16 Jan 2024 04:00:00 -0500 Charles River Charles River 1686 For the 850 million people around the world suffering from chronic kidney disease, the grind of dialysis treatment can wear them down in more ways than one.   

 

Dr. Andy Herbert, co-founder of Invizius, is out to change that. This five-year-old company started from humble beginnings and is currently developing H-Guard® Priming Solution, which increases the effectiveness of dialysis while negating, or eliminating, its potentially dangerous side effects. It will be used in an upcoming first-in-human clinical trial and has the potential to improve patients’ quality of life – both physically and mentally.  

 

Join Dr. Herbert as we discuss the origins of Invizius, how H-Guard works, why dialysis can take a toll on mental health, and how working with a strategic partner has helped Invizius progress this treatment.

Show Notes  

 
Invizius 

Charles River's Nonclinical Support Helps Invizius Secure MHRA Approval for First-in-Human Trial of H-Guard® Hemodialysis Solution 

Renal Disorders | Charles River 

Preclinical CRO Services for Safety Assessment 

Inflammation | Charles River

]]> immunology, kidney disease, dialysis, pharmacology, toxicology, Andy Herbert, H-Guard, life sciences, biotech, pharma, CRO, drug development No Checking Vitals: The Disruptors 5 5 4 4 Checking Vitals: The Disruptors full 651a6dd0-c71c-45e8-8237-2212951646bb https://share.transistor.fm/s/6ee9491f Over the past 12 months, we have shared some remarkable stories from the scientific community, but three of the most impactful have come from “Disruptors” in their respective fields. Relive these stories with our hosts on the year-end edition of Vital Science.

Show Notes  

  

]]> Over the past 12 months, we have shared some remarkable stories from the scientific community, but three of the most impactful have come from “Disruptors” in their respective fields. Relive these stories with our hosts on the year-end edition of Vital Science.

Show Notes  

  

]]> Tue, 19 Dec 2023 04:00:00 -0500 Charles River Charles River 617 Over the past 12 months, we have shared some remarkable stories from the scientific community, but three of the most impactful have come from “Disruptors” in their respective fields. Relive these stories with our hosts on the year-end edition of Vital Science.

Show Notes  

  

]]> gene therapy, rare disease, CNS disorders, Valerie Estess, Lisa Deschamps, Wise Young, life sciences, biotech, pharma, CRO, drug development No TREND: The Online Community Making a Difference 5 5 3 3 TREND: The Online Community Making a Difference full 232510e0-4ed8-483e-800e-3f02e7e946db https://share.transistor.fm/s/8afa9d13 When Maria Picone’s daughter was diagnosed with Prader-Willi Syndrome (PWS), she turned to the internet for answers.  

 

What she found was an online community of caregivers sharing their experiences with PWS, giving her comfort and direction with what to do about her daughter’s rare disease. It also spurred her and her husband to create TREND Community, an online platform for caregivers of rare diseases to not only share their experiences, but also make positive contributions to scientific literature.  

 

Join us as we discuss the philosophy of TREND Community, how it transforms general discussions into real-world clinical research, how collaboration drives their progress, what’s next for TREND, and what you can do to help advance their mission.   

 
Show Notes

 

Trend Community - Impact Through Insights

Trend Community Report on Identifying Mental Health Challenges Experienced by Caregivers in Rare Disease Communities: A Social Media Analysis

Charles River | Rare Disease

The Disruptors: Innovation in Drug Discovery

]]> When Maria Picone’s daughter was diagnosed with Prader-Willi Syndrome (PWS), she turned to the internet for answers.  

 

What she found was an online community of caregivers sharing their experiences with PWS, giving her comfort and direction with what to do about her daughter’s rare disease. It also spurred her and her husband to create TREND Community, an online platform for caregivers of rare diseases to not only share their experiences, but also make positive contributions to scientific literature.  

 

Join us as we discuss the philosophy of TREND Community, how it transforms general discussions into real-world clinical research, how collaboration drives their progress, what’s next for TREND, and what you can do to help advance their mission.   

 
Show Notes

 

Trend Community - Impact Through Insights

Trend Community Report on Identifying Mental Health Challenges Experienced by Caregivers in Rare Disease Communities: A Social Media Analysis

Charles River | Rare Disease

The Disruptors: Innovation in Drug Discovery

]]> Tue, 14 Nov 2023 04:00:00 -0500 Charles River Charles River 2680 When Maria Picone’s daughter was diagnosed with Prader-Willi Syndrome (PWS), she turned to the internet for answers.  

 

What she found was an online community of caregivers sharing their experiences with PWS, giving her comfort and direction with what to do about her daughter’s rare disease. It also spurred her and her husband to create TREND Community, an online platform for caregivers of rare diseases to not only share their experiences, but also make positive contributions to scientific literature.  

 

Join us as we discuss the philosophy of TREND Community, how it transforms general discussions into real-world clinical research, how collaboration drives their progress, what’s next for TREND, and what you can do to help advance their mission.   

 
Show Notes

 

Trend Community - Impact Through Insights

Trend Community Report on Identifying Mental Health Challenges Experienced by Caregivers in Rare Disease Communities: A Social Media Analysis

Charles River | Rare Disease

The Disruptors: Innovation in Drug Discovery

]]> Maria Picone, TREND, rare disease, social listening, Prader-Willi Syndrome, life sciences, biotech, pharma, pharmaceutical, CRO, drug development No Strength in Numbers 5 5 2 2 Strength in Numbers full cf214473-005f-4824-9450-7f06281b09f2 https://share.transistor.fm/s/36936404 Imagine a world where your child has a rare disease that’s so rare, it doesn’t have a name and only a handful of people around the world have a similar condition. It can leave you feeling helpless and alone knowing the odds are stacked against you. 

 

This is the situation Bo Bigelow experienced with his daughter, Tess. She suffers from a USP7, a neurodevelopmental disorder that impacts her motor function, speech, and bone development. Tess’ condition left Bo looking for help… and he found a lot of other patients and families with other ultra-rare diseases that wanted to share their stories too. Today, Bo’s initiatives have given hope to other people and help them find strength in knowing they’re not alone. 

 

Join us as we discuss the ways Bo documented his daughter’s journey, learn more about USP7-related diseases and their impact, how Bo created the Disorder Channel as a way for other rare disease patients to tell their stories, what progress is being made to learn more about Tess’ condition through the Foundation for USP7-Related Diseases, and how you can help advance their research. 


Show Notes

 

Rare Disease | Charles River

Foundation for USP-7 Related Diseases

Stronger Every Day Blog

Stronger Every Day Podcast

The Disorder Channel

  

]]> Imagine a world where your child has a rare disease that’s so rare, it doesn’t have a name and only a handful of people around the world have a similar condition. It can leave you feeling helpless and alone knowing the odds are stacked against you. 

 

This is the situation Bo Bigelow experienced with his daughter, Tess. She suffers from a USP7, a neurodevelopmental disorder that impacts her motor function, speech, and bone development. Tess’ condition left Bo looking for help… and he found a lot of other patients and families with other ultra-rare diseases that wanted to share their stories too. Today, Bo’s initiatives have given hope to other people and help them find strength in knowing they’re not alone. 

 

Join us as we discuss the ways Bo documented his daughter’s journey, learn more about USP7-related diseases and their impact, how Bo created the Disorder Channel as a way for other rare disease patients to tell their stories, what progress is being made to learn more about Tess’ condition through the Foundation for USP7-Related Diseases, and how you can help advance their research. 


Show Notes

 

Rare Disease | Charles River

Foundation for USP-7 Related Diseases

Stronger Every Day Blog

Stronger Every Day Podcast

The Disorder Channel

  

]]> Tue, 17 Oct 2023 12:49:45 -0400 Charles River Charles River 3246 Imagine a world where your child has a rare disease that’s so rare, it doesn’t have a name and only a handful of people around the world have a similar condition. It can leave you feeling helpless and alone knowing the odds are stacked against you. 

 

This is the situation Bo Bigelow experienced with his daughter, Tess. She suffers from a USP7, a neurodevelopmental disorder that impacts her motor function, speech, and bone development. Tess’ condition left Bo looking for help… and he found a lot of other patients and families with other ultra-rare diseases that wanted to share their stories too. Today, Bo’s initiatives have given hope to other people and help them find strength in knowing they’re not alone. 

 

Join us as we discuss the ways Bo documented his daughter’s journey, learn more about USP7-related diseases and their impact, how Bo created the Disorder Channel as a way for other rare disease patients to tell their stories, what progress is being made to learn more about Tess’ condition through the Foundation for USP7-Related Diseases, and how you can help advance their research. 


Show Notes

 

Rare Disease | Charles River

Foundation for USP-7 Related Diseases

Stronger Every Day Blog

Stronger Every Day Podcast

The Disorder Channel

  

]]> life sciences, biotech, pharma, CRO, drug development No Emily Whitehead: Pioneer and Hero 5 5 1 1 Emily Whitehead: Pioneer and Hero full d5597574-12d1-4b7c-ab8a-f58e1172eb59 https://share.transistor.fm/s/e70b9eb9 18-year-old Emily Whitehead aspires to be a writer, but nothing could have prepared her for the plot twist that struck her as a child.  

 

In the space of just 24 hours, five-year-old Emily suffered from various symptoms that culminated in a diagnosis of acute lymphoblastic leukemia (ALL). After almost two years of failed chemotherapy treatments, her family turned towards an experimental CAR-T therapy that had been successful with adults but never been used on a child. Three weeks later, Emily became the first child in the world to beat her cancer by “training” her immune system to fight these malicious cells.  

 

Join Emily and her father, Tom, as they relive the chain of events that led to her diagnosis, what helped her stay calm as she underwent this experimental treatment, and how the Emily Whitehead Foundation aims to help others who are going through pediatric cancer treatment.

Show Notes  

  

Emily Whitehead Foundation 

Vital Science S3 E02: Can MILs Strike a Killer Blow to Cancer? 

World Congress Event Page | Charles River 

Cell and Gene Therapy | Charles River 

Oncology CRO Services | Charles River 


]]> 18-year-old Emily Whitehead aspires to be a writer, but nothing could have prepared her for the plot twist that struck her as a child.  

 

In the space of just 24 hours, five-year-old Emily suffered from various symptoms that culminated in a diagnosis of acute lymphoblastic leukemia (ALL). After almost two years of failed chemotherapy treatments, her family turned towards an experimental CAR-T therapy that had been successful with adults but never been used on a child. Three weeks later, Emily became the first child in the world to beat her cancer by “training” her immune system to fight these malicious cells.  

 

Join Emily and her father, Tom, as they relive the chain of events that led to her diagnosis, what helped her stay calm as she underwent this experimental treatment, and how the Emily Whitehead Foundation aims to help others who are going through pediatric cancer treatment.

Show Notes  

  

Emily Whitehead Foundation 

Vital Science S3 E02: Can MILs Strike a Killer Blow to Cancer? 

World Congress Event Page | Charles River 

Cell and Gene Therapy | Charles River 

Oncology CRO Services | Charles River 


]]> Tue, 19 Sep 2023 04:00:00 -0400 Charles River Charles River 2009 18-year-old Emily Whitehead aspires to be a writer, but nothing could have prepared her for the plot twist that struck her as a child.  

 

In the space of just 24 hours, five-year-old Emily suffered from various symptoms that culminated in a diagnosis of acute lymphoblastic leukemia (ALL). After almost two years of failed chemotherapy treatments, her family turned towards an experimental CAR-T therapy that had been successful with adults but never been used on a child. Three weeks later, Emily became the first child in the world to beat her cancer by “training” her immune system to fight these malicious cells.  

 

Join Emily and her father, Tom, as they relive the chain of events that led to her diagnosis, what helped her stay calm as she underwent this experimental treatment, and how the Emily Whitehead Foundation aims to help others who are going through pediatric cancer treatment.

Show Notes  

  

Emily Whitehead Foundation 

Vital Science S3 E02: Can MILs Strike a Killer Blow to Cancer? 

World Congress Event Page | Charles River 

Cell and Gene Therapy | Charles River 

Oncology CRO Services | Charles River 


]]> life sciences, biotech, pharma, CRO, drug development No Modernizing Drug Development 4 4 10 10 Modernizing Drug Development full 9422d485-3f67-4960-bfdb-e7e8fe8b2018 https://share.transistor.fm/s/e494f42b For decades, researchers have utilized animal models to help predict the effects of a drug compound in humans.  

 

With recent advances in technology and the passage of the FDA Modernization Act 2.0, researchers are increasingly looking at new methods to refine, reduce, and replace in vivo testing to advance drug candidates. However, one important question remains – how are all these modern advancements and laws driving progress in drug discovery?  

 

Find out as Michael Templin, a member of Charles River’s Scientific Advisory Services team, joins us for a look at the impacts of this legislation on regulatory submission for biosimilars, how improving animal welfare will make drug development better, and what knowledge a CRO can bring to optimize projects.

Show Notes


]]> For decades, researchers have utilized animal models to help predict the effects of a drug compound in humans.  

 

With recent advances in technology and the passage of the FDA Modernization Act 2.0, researchers are increasingly looking at new methods to refine, reduce, and replace in vivo testing to advance drug candidates. However, one important question remains – how are all these modern advancements and laws driving progress in drug discovery?  

 

Find out as Michael Templin, a member of Charles River’s Scientific Advisory Services team, joins us for a look at the impacts of this legislation on regulatory submission for biosimilars, how improving animal welfare will make drug development better, and what knowledge a CRO can bring to optimize projects.

Show Notes


]]> Tue, 18 Jul 2023 04:00:00 -0400 Charles River Charles River 1558 For decades, researchers have utilized animal models to help predict the effects of a drug compound in humans.  

 

With recent advances in technology and the passage of the FDA Modernization Act 2.0, researchers are increasingly looking at new methods to refine, reduce, and replace in vivo testing to advance drug candidates. However, one important question remains – how are all these modern advancements and laws driving progress in drug discovery?  

 

Find out as Michael Templin, a member of Charles River’s Scientific Advisory Services team, joins us for a look at the impacts of this legislation on regulatory submission for biosimilars, how improving animal welfare will make drug development better, and what knowledge a CRO can bring to optimize projects.

Show Notes


]]> FDA, FDA Modernization Act, Research Models and Services, basic research, life sciences, biotech, pharma, pharmaceutical, CRO, drug development No SCA3: A Family Affair 4 4 9 9 SCA3: A Family Affair full bb8bd688-033e-4b08-9b68-6155e8bba30f https://share.transistor.fm/s/fcaa384a Spinocerebellar ataxia type 3 (SCA3) is a neuromuscular disease affecting just 50,000 people in the United States, including three generations of the Klassen family.  

 

Greg Klassen, his father, and his son have all been diagnosed with this rare condition that impacts the central nervous system, affecting balance, coordination, and mood. Motivated by the 50/50 chance his son Jeff will develop its unforgiving symptoms, Greg joined the board of the Cure Rare Disease foundation and is currently in touch with the efforts being made to develop a treatment that will improve his quality of life and others affected by SCA3.  

 

Join us for a conversation on how Greg copes with SCA3 in his own life, what the rare disease community is doing to raise awareness, how antisense oligonucleotides (ASOs) could lead to a potential treatment, and what it would mean to him if a cure was developed.

Show Notes

]]> Spinocerebellar ataxia type 3 (SCA3) is a neuromuscular disease affecting just 50,000 people in the United States, including three generations of the Klassen family.  

 

Greg Klassen, his father, and his son have all been diagnosed with this rare condition that impacts the central nervous system, affecting balance, coordination, and mood. Motivated by the 50/50 chance his son Jeff will develop its unforgiving symptoms, Greg joined the board of the Cure Rare Disease foundation and is currently in touch with the efforts being made to develop a treatment that will improve his quality of life and others affected by SCA3.  

 

Join us for a conversation on how Greg copes with SCA3 in his own life, what the rare disease community is doing to raise awareness, how antisense oligonucleotides (ASOs) could lead to a potential treatment, and what it would mean to him if a cure was developed.

Show Notes

]]> Tue, 20 Jun 2023 10:36:37 -0400 Charles River Charles River 1429 Spinocerebellar ataxia type 3 (SCA3) is a neuromuscular disease affecting just 50,000 people in the United States, including three generations of the Klassen family.  

 

Greg Klassen, his father, and his son have all been diagnosed with this rare condition that impacts the central nervous system, affecting balance, coordination, and mood. Motivated by the 50/50 chance his son Jeff will develop its unforgiving symptoms, Greg joined the board of the Cure Rare Disease foundation and is currently in touch with the efforts being made to develop a treatment that will improve his quality of life and others affected by SCA3.  

 

Join us for a conversation on how Greg copes with SCA3 in his own life, what the rare disease community is doing to raise awareness, how antisense oligonucleotides (ASOs) could lead to a potential treatment, and what it would mean to him if a cure was developed.

Show Notes

]]> gene therapy, rare disease, SCA3, Spinocerebellar ataxia, CNS, ASOs, antisense oligonucleotide, life sciences, biotech, pharma, CRO, drug development No Moving FAST to Treat Angelman Syndrome 4 4 8 8 Moving FAST to Treat Angelman Syndrome full e1532466-4240-4f4e-879e-b1a76f12f415 https://share.transistor.fm/s/ce4dc0e6 The effects of Angelman Syndrome (AS) on young children are debilitating. From an early age, they face an uphill battle with this neurogenetic disease’s unrelenting symptoms, including seizures, cognitive impairments, and loss of motor function. 


It can also be tough on caretakers – just ask Dr. Allyson Berent and Jennifer Panagoulias. They both have personal connections to this disease, which in Dr. Berent’s case led to her creating the Foundation for Angelman Syndrome Therapeutics (FAST) in 2008. Today, Panagoulias, whose niece has AS, serves as their head of Regulatory and Policy, tasked with the responsibility to find a path that will develop treatments to improve the quality of life for both patients and caregivers.  


Join Jennifer as we discuss the origins of FAST, the science behind Angelman Syndrome, the crucial role outside partnerships have played in research, and what’s in the pipeline for potential therapeutics.

Show Notes 

]]> The effects of Angelman Syndrome (AS) on young children are debilitating. From an early age, they face an uphill battle with this neurogenetic disease’s unrelenting symptoms, including seizures, cognitive impairments, and loss of motor function. 


It can also be tough on caretakers – just ask Dr. Allyson Berent and Jennifer Panagoulias. They both have personal connections to this disease, which in Dr. Berent’s case led to her creating the Foundation for Angelman Syndrome Therapeutics (FAST) in 2008. Today, Panagoulias, whose niece has AS, serves as their head of Regulatory and Policy, tasked with the responsibility to find a path that will develop treatments to improve the quality of life for both patients and caregivers.  


Join Jennifer as we discuss the origins of FAST, the science behind Angelman Syndrome, the crucial role outside partnerships have played in research, and what’s in the pipeline for potential therapeutics.

Show Notes 

]]> Tue, 16 May 2023 04:00:00 -0400 Charles River Charles River 1842 The effects of Angelman Syndrome (AS) on young children are debilitating. From an early age, they face an uphill battle with this neurogenetic disease’s unrelenting symptoms, including seizures, cognitive impairments, and loss of motor function. 


It can also be tough on caretakers – just ask Dr. Allyson Berent and Jennifer Panagoulias. They both have personal connections to this disease, which in Dr. Berent’s case led to her creating the Foundation for Angelman Syndrome Therapeutics (FAST) in 2008. Today, Panagoulias, whose niece has AS, serves as their head of Regulatory and Policy, tasked with the responsibility to find a path that will develop treatments to improve the quality of life for both patients and caregivers.  


Join Jennifer as we discuss the origins of FAST, the science behind Angelman Syndrome, the crucial role outside partnerships have played in research, and what’s in the pipeline for potential therapeutics.

Show Notes 

]]> gene therapy, rare disease, FAST, Angelman, Angelman Syndrome, ASOs, antisense oligonucleotide, Allyson Berent, Jennifer Panagoulias, therapeutic, life sciences, biotech, pharma, CRO, drug development No Free for Life: The Story of n-Lorem Foundation 4 4 7 7 Free for Life: The Story of n-Lorem Foundation full 74a9036b-56b8-4aaf-b7ad-8e7bf4011280 https://share.transistor.fm/s/8fd97edb When patients face the diagnosis of a rare disease, they face a costly, uphill battle to develop a treatment for their condition… that is, if they ever do.  

 

Dr. Stanley Crooke is aiming to change that. As the CEO of n-Lorem Foundation, his mission is to provide personalized treatments to ultra-rare disease patients for free as long as they live, no questions asked. Thanks to his humility, coupled with the generosity of other individuals and companies, ultra-rare disease patients have a renewed hope to get the treatments others may not be able to provide.  

 

Join Dr. Crooke as he reflects on his humble beginnings at Ionis, the approach n-Lorem takes to developing drugs for ultra-rare diseases, and what the future holds for research in this area.

Show Notes 

]]> When patients face the diagnosis of a rare disease, they face a costly, uphill battle to develop a treatment for their condition… that is, if they ever do.  

 

Dr. Stanley Crooke is aiming to change that. As the CEO of n-Lorem Foundation, his mission is to provide personalized treatments to ultra-rare disease patients for free as long as they live, no questions asked. Thanks to his humility, coupled with the generosity of other individuals and companies, ultra-rare disease patients have a renewed hope to get the treatments others may not be able to provide.  

 

Join Dr. Crooke as he reflects on his humble beginnings at Ionis, the approach n-Lorem takes to developing drugs for ultra-rare diseases, and what the future holds for research in this area.

Show Notes 

]]> Tue, 18 Apr 2023 04:00:00 -0400 Charles River Charles River 1841 When patients face the diagnosis of a rare disease, they face a costly, uphill battle to develop a treatment for their condition… that is, if they ever do.  

 

Dr. Stanley Crooke is aiming to change that. As the CEO of n-Lorem Foundation, his mission is to provide personalized treatments to ultra-rare disease patients for free as long as they live, no questions asked. Thanks to his humility, coupled with the generosity of other individuals and companies, ultra-rare disease patients have a renewed hope to get the treatments others may not be able to provide.  

 

Join Dr. Crooke as he reflects on his humble beginnings at Ionis, the approach n-Lorem takes to developing drugs for ultra-rare diseases, and what the future holds for research in this area.

Show Notes 

]]> gene therapy, rare disease, n-Lorem, Stanley Crooke, Ionis, ASOs, antisense oligonucleotide, life sciences, biotech, pharma, CRO, drug development No Evie's Story Revisited 4 4 6 6 Evie's Story Revisited full 221d3c82-9fb9-4a06-8195-b156e380a969 https://share.transistor.fm/s/0e5e44dc Imagine being diagnosed with an incurable rare disease before ever being born. This is the reality that Evie faced when she was diagnosed with hypophosphatasia, a condition impacting bone growth, breathing, and mobility, and often gives patients just 18 months to live.   

 

Luckily, her story doesn’t end there. At three months old, she enrolled in a clinical trial for a first-of-its-kind medication that her mom Lindsey claims “probably saved her life”. Today, Evie is 13 years old and continues to defy the odds, giving hope to other young children suffering from a rare disease that they too can find the strength to overcome anything life throws at them.  

 

Join Evie and Lindsey for this emotional look at their journey, how the power of collaboration has helped them along the way, and Evie’s goals for the future.

Show Notes 

]]> Imagine being diagnosed with an incurable rare disease before ever being born. This is the reality that Evie faced when she was diagnosed with hypophosphatasia, a condition impacting bone growth, breathing, and mobility, and often gives patients just 18 months to live.   

 

Luckily, her story doesn’t end there. At three months old, she enrolled in a clinical trial for a first-of-its-kind medication that her mom Lindsey claims “probably saved her life”. Today, Evie is 13 years old and continues to defy the odds, giving hope to other young children suffering from a rare disease that they too can find the strength to overcome anything life throws at them.  

 

Join Evie and Lindsey for this emotional look at their journey, how the power of collaboration has helped them along the way, and Evie’s goals for the future.

Show Notes 

]]> Tue, 21 Mar 2023 04:00:00 -0400 Charles River Charles River 1756 Imagine being diagnosed with an incurable rare disease before ever being born. This is the reality that Evie faced when she was diagnosed with hypophosphatasia, a condition impacting bone growth, breathing, and mobility, and often gives patients just 18 months to live.   

 

Luckily, her story doesn’t end there. At three months old, she enrolled in a clinical trial for a first-of-its-kind medication that her mom Lindsey claims “probably saved her life”. Today, Evie is 13 years old and continues to defy the odds, giving hope to other young children suffering from a rare disease that they too can find the strength to overcome anything life throws at them.  

 

Join Evie and Lindsey for this emotional look at their journey, how the power of collaboration has helped them along the way, and Evie’s goals for the future.

Show Notes 

]]> metabolic disease, rare disease, Evie, HPP, Hypophosphatasia, Strensiq, life sciences, biotech, pharma, CRO, drug development No Neurogenesis: Regenerating Hope 4 4 5 5 Neurogenesis: Regenerating Hope full 5c9b7f2d-51f0-4549-8b9d-00a639c9a74d https://share.transistor.fm/s/ca70ce97 Could it be possible to regenerate neurons in the human body? 

 

It’s a question that has driven Dr. Wise Young for over 40 years. He’s dedicated his career to researching spinal cord injuries and how to develop a treatment for them. Along the way, he’s discovered neurogenesis, a way to regenerate neurons in not just the spinal cord, but also the brain. Thanks to his work, what everybody told him was once impossible, is now close to becoming a reality.  

 

Join us as Dr. Young discusses his founding of, and work at, the W.M. Keck Center for Collaborative Neuroscience, how the components of stem cells and umbilical cord blood can help regenerate neurons, and what his vision is for the future of research in this growing field.

Show Notes 

]]> Could it be possible to regenerate neurons in the human body? 

 

It’s a question that has driven Dr. Wise Young for over 40 years. He’s dedicated his career to researching spinal cord injuries and how to develop a treatment for them. Along the way, he’s discovered neurogenesis, a way to regenerate neurons in not just the spinal cord, but also the brain. Thanks to his work, what everybody told him was once impossible, is now close to becoming a reality.  

 

Join us as Dr. Young discusses his founding of, and work at, the W.M. Keck Center for Collaborative Neuroscience, how the components of stem cells and umbilical cord blood can help regenerate neurons, and what his vision is for the future of research in this growing field.

Show Notes 

]]> Tue, 21 Feb 2023 04:00:00 -0500 Charles River Charles River 1651 Could it be possible to regenerate neurons in the human body? 

 

It’s a question that has driven Dr. Wise Young for over 40 years. He’s dedicated his career to researching spinal cord injuries and how to develop a treatment for them. Along the way, he’s discovered neurogenesis, a way to regenerate neurons in not just the spinal cord, but also the brain. Thanks to his work, what everybody told him was once impossible, is now close to becoming a reality.  

 

Join us as Dr. Young discusses his founding of, and work at, the W.M. Keck Center for Collaborative Neuroscience, how the components of stem cells and umbilical cord blood can help regenerate neurons, and what his vision is for the future of research in this growing field.

Show Notes 

]]> neuroscience, neurons, neurogenesis, cell therapy, inflammation, spinal cord, spinal cord injury, SCI, life sciences, biotech, pharma, CRO, drug development No AviadoBio: Bold and Courageous 4 4 4 4 AviadoBio: Bold and Courageous full 39c84aac-8244-449f-95a3-3cd1795790ad https://share.transistor.fm/s/36a6125b Recent advancements in research has led to the development of effective therapeutics to combat neurodegenerative diseases, giving patients a renewed sense of hope there will ultimately be a more effective treatment.

CEO Lisa Deschamps and her team at AviadoBio are among those conducting research in the space, but they’re doing things a little differently. They’ve been given a unique drug designation by the FDA to develop a treatment for frontotemporal dementia (FTD), a crippling neurodegenerative disorder that affects neuron production in people under 65. It may be a “bold and courageous” undertaking, but the benefits could affect future generations to come.

Join us as we take a look at the motivation behind the work AviadoBio is doing, what makes their therapy unique, and Lisa’s vision for their future.

Show Notes 

]]> Recent advancements in research has led to the development of effective therapeutics to combat neurodegenerative diseases, giving patients a renewed sense of hope there will ultimately be a more effective treatment.

CEO Lisa Deschamps and her team at AviadoBio are among those conducting research in the space, but they’re doing things a little differently. They’ve been given a unique drug designation by the FDA to develop a treatment for frontotemporal dementia (FTD), a crippling neurodegenerative disorder that affects neuron production in people under 65. It may be a “bold and courageous” undertaking, but the benefits could affect future generations to come.

Join us as we take a look at the motivation behind the work AviadoBio is doing, what makes their therapy unique, and Lisa’s vision for their future.

Show Notes 

]]> Tue, 17 Jan 2023 04:00:00 -0500 Charles River Charles River 1869 AviadoBio CEO Lisa Deschamps discusses the unique approach her team is taking to deliver a therapeutic for frontotemporal dementia and other neurodegenerative diseases. AviadoBio CEO Lisa Deschamps discusses the unique approach her team is taking to deliver a therapeutic for frontotemporal dementia and other neurodegenerative diseases. AviadoBio, neuroscience, neurodegenerative disorders, gene therapy, FTD, Frontotemporal Dementia, life sciences, biotech, pharma, CRO, drug development No Checking Vitals 4 4 3 3 Checking Vitals full 6a7931b5-71a4-4bc2-88db-23b5c1aa493d https://share.transistor.fm/s/2770ca01 As we close in on the end of 2022, we’ve had the privilege to interview some amazing people who are doing great work with drug discovery.   

Join Gina Mullane and Todd Poley as we reflect on some of the memorable moments and guests from this season, including an update on Amylyx Pharmaceuticals’ new ALS treatment, Chris Claussen’s discussion on the positive impacts of psychedelic drugs, and the work of Project ALS to develop a treatment for this crippling disease.

On behalf of our entire team, thank you for listening this year. We hope you’ll join us for an exciting lineup of remarkable stories set to premiere in 2023.

Show Notes:

]]> As we close in on the end of 2022, we’ve had the privilege to interview some amazing people who are doing great work with drug discovery.   

Join Gina Mullane and Todd Poley as we reflect on some of the memorable moments and guests from this season, including an update on Amylyx Pharmaceuticals’ new ALS treatment, Chris Claussen’s discussion on the positive impacts of psychedelic drugs, and the work of Project ALS to develop a treatment for this crippling disease.

On behalf of our entire team, thank you for listening this year. We hope you’ll join us for an exciting lineup of remarkable stories set to premiere in 2023.

Show Notes:

]]> Tue, 13 Dec 2022 04:00:00 -0500 Charles River Charles River 951 Gina Mullane and Todd Poley get together to discuss some of the memorable moments and clips from 2022. Gina Mullane and Todd Poley get together to discuss some of the memorable moments and clips from 2022. life sciences, biotech, pharma, CRO, drug development No A Father’s Race Against Time 4 4 2 2 A Father’s Race Against Time full 4e0a0d60-892f-45b6-9e27-2de0f69fa154 https://share.transistor.fm/s/8fa6b9e1 Spastic Paraplegia 50 (SPG50) is a neurodegenerative and neurodevelopmental disorder that is known to affect only 80 people around the world, including just one person in Canada.  

 

Unfortunately for Terry Pirovolakis, it happens to be his son, Michael. As a result, he’s teamed up with gene therapy experts, CROs, and nonprofits to research, manufacture, and deliver a therapy to help his son and others suffering from this ultra-rare disease, but the clock is ticking.   

 

Join us as Terry discusses his grassroots efforts to raise money and found the Cure SPG50 Foundation, how SPG50 affects the body, the future of research and development for this disease, and what you can do to help Terry’s efforts. 

Show Notes:

]]> Spastic Paraplegia 50 (SPG50) is a neurodegenerative and neurodevelopmental disorder that is known to affect only 80 people around the world, including just one person in Canada.  

 

Unfortunately for Terry Pirovolakis, it happens to be his son, Michael. As a result, he’s teamed up with gene therapy experts, CROs, and nonprofits to research, manufacture, and deliver a therapy to help his son and others suffering from this ultra-rare disease, but the clock is ticking.   

 

Join us as Terry discusses his grassroots efforts to raise money and found the Cure SPG50 Foundation, how SPG50 affects the body, the future of research and development for this disease, and what you can do to help Terry’s efforts. 

Show Notes:

]]> Tue, 15 Nov 2022 04:00:00 -0500 Charles River Charles River 1780 Terry Pirovolakis is in a race against time to find a treatment for his son’s ultra-rare disease. Terry Pirovolakis is in a race against time to find a treatment for his son’s ultra-rare disease. gene therapy, rare disease, SPG50, CureSPG50, life sciences, biotech, pharma, CRO, drug development No Project ALS: Fueled by Love 4 4 1 1 Project ALS: Fueled by Love full a2916ac1-f8eb-4e51-ad41-39da69e63d05 https://share.transistor.fm/s/dff57187 For Valerie Estess, finding a cure for ALS is personal.

Her sister, Jenifer, was diagnosed with this crippling disease in 1998, which led to the founding of Project ALS, a nonprofit designed to raise awareness and eventually find a cure. Nearly 25 years later, they have raised over $100 million and helped develop Jacifusen, the first therapy designed to help treat ALS. However, Valerie believes their work is far from finished.

Join us for an intimate discussion on the origins of Project ALS, their collaborative efforts with leading scientists, academic institutions, and contract research organizations to further their knowledge of the disease, and what lies ahead for Project ALS’ mission and research.

SHOW NOTES

]]> For Valerie Estess, finding a cure for ALS is personal.

Her sister, Jenifer, was diagnosed with this crippling disease in 1998, which led to the founding of Project ALS, a nonprofit designed to raise awareness and eventually find a cure. Nearly 25 years later, they have raised over $100 million and helped develop Jacifusen, the first therapy designed to help treat ALS. However, Valerie believes their work is far from finished.

Join us for an intimate discussion on the origins of Project ALS, their collaborative efforts with leading scientists, academic institutions, and contract research organizations to further their knowledge of the disease, and what lies ahead for Project ALS’ mission and research.

SHOW NOTES

]]> Tue, 20 Sep 2022 04:00:00 -0400 Charles River Charles River 2117 If you ask Valerie Estess what fuels the efforts of Project ALS, the answer is simple – love. Today, they’re more motivated than ever to find suitable treatments for this crippling disease. If you ask Valerie Estess what fuels the efforts of Project ALS, the answer is simple – love. Today, they’re more motivated than ever to find suitable treatments for this crippling disease. neuroscience, rare disease, ALS, ASO, Amyotrophic lateral sclerosis, nervous system, muscle movement, life sciences, biotech, pharma, CRO, drug development No Logica– Drug Discovery Made Smarter 3 3 10 10 Logica– Drug Discovery Made Smarter full 8378cc26-08cd-4850-a188-c7c3eebbef3a https://share.transistor.fm/s/0105b578 What happens when you combine an industry-altering, AI-powered platform with a leading CRO's preclinical expertise? 

 

That’s what Valo Health and Charles River are answering with the introduction of Logica™. This revolutionary platform aims to accelerate drug discovery and development by finding the most viable molecules faster, helping biotechs and pharma focus their resources only on the ones that will evolve into therapies that patients will receive more quickly.  

 

Join Guido Lanza (Valo) and Julie Frearson (Charles River) as they discuss the components of Logica™, what makes it unique from other platforms, and how it will transform the future of drug discovery.  
 

Show Notes 

]]> What happens when you combine an industry-altering, AI-powered platform with a leading CRO's preclinical expertise? 

 

That’s what Valo Health and Charles River are answering with the introduction of Logica™. This revolutionary platform aims to accelerate drug discovery and development by finding the most viable molecules faster, helping biotechs and pharma focus their resources only on the ones that will evolve into therapies that patients will receive more quickly.  

 

Join Guido Lanza (Valo) and Julie Frearson (Charles River) as they discuss the components of Logica™, what makes it unique from other platforms, and how it will transform the future of drug discovery.  
 

Show Notes 

]]> Tue, 19 Jul 2022 04:00:00 -0400 Charles River Charles River 2111 Find out how Logica™ combines AI capabilities with data generating power to reinvent drug discovery. Find out how Logica™ combines AI capabilities with data generating power to reinvent drug discovery. chemical, life sciences, biotech, pharma, pharmaceutical, CRO, drug development No Retrogenix: The Screen Door of Drug Development 3 3 9 9 Retrogenix: The Screen Door of Drug Development full 7430024c-f0f0-47e0-8153-c11534af600b https://share.transistor.fm/s/1fc95588 Drug developers face long odds and complex regulatory challenges when it comes to crafting a suitable candidate. In fact, only one of every 10 drug candidates gain regulatory approval, and when they do, it takes an average of 14 years and costs well over $2 billion.  

 

So what makes for a successful candidate? It starts with a suitable screening platform that identifies targets and the molecules that bind to them to create a therapeutic response. Retrogenix is one such platform that the top 20 drug developers in the world currently use to increase their chances of success thanks to its unique technology that doesn’t require animal models or human tissue to evaluate effectiveness.  

 

Join us to find out how Retrogenix works to identify targets, accelerate drug development, get vulnerable patients the therapies they need more quickly, and adapt to meet the growing demands of regulatory agencies. 

Show Notes 

]]> Drug developers face long odds and complex regulatory challenges when it comes to crafting a suitable candidate. In fact, only one of every 10 drug candidates gain regulatory approval, and when they do, it takes an average of 14 years and costs well over $2 billion.  

 

So what makes for a successful candidate? It starts with a suitable screening platform that identifies targets and the molecules that bind to them to create a therapeutic response. Retrogenix is one such platform that the top 20 drug developers in the world currently use to increase their chances of success thanks to its unique technology that doesn’t require animal models or human tissue to evaluate effectiveness.  

 

Join us to find out how Retrogenix works to identify targets, accelerate drug development, get vulnerable patients the therapies they need more quickly, and adapt to meet the growing demands of regulatory agencies. 

Show Notes 

]]> Tue, 21 Jun 2022 04:00:00 -0400 Charles River Charles River 1184 Tune in to hear about the Retrogenix screening library and how developers use it to gain confidence when developing safe and effective drugs. Tune in to hear about the Retrogenix screening library and how developers use it to gain confidence when developing safe and effective drugs. immuno-oncology, immunology, cancer, oncology, rare disease, biologic, vaccine, life sciences, biotech, pharma, CRO, drug development No Open Science: The Parallel Universe 3 3 8 8 Open Science: The Parallel Universe full ce55fe3a-9604-4674-998b-d80fa44adf83 https://share.transistor.fm/s/81d15f96 Aled Edwards’ vision of science is set to shake the foundation of drug discovery and development as we know it.  

 

The Director of M4K Pharma and CEO of the Structural Genomics Consortium is leading the charge for a more open scientific approach. It’s a parallel universe where scientists can work together and get therapies designed to treat rare diseases in the hands of patients even faster – one that isn’t bound by patents, siloes, and profits. 

 

Join Aled as he discusses the “open science” approach, the current state of the pharmaceutical industry, and what the future holds for genetic biology.

Show Notes 

Resources 

  

]]> Aled Edwards’ vision of science is set to shake the foundation of drug discovery and development as we know it.  

 

The Director of M4K Pharma and CEO of the Structural Genomics Consortium is leading the charge for a more open scientific approach. It’s a parallel universe where scientists can work together and get therapies designed to treat rare diseases in the hands of patients even faster – one that isn’t bound by patents, siloes, and profits. 

 

Join Aled as he discusses the “open science” approach, the current state of the pharmaceutical industry, and what the future holds for genetic biology.

Show Notes 

Resources 

  

]]> Tue, 17 May 2022 04:00:00 -0400 Charles River Charles River 1685 Aled Edwards’ vision of science is set to shake the foundation of drug discovery and development as we know it. Aled Edwards’ vision of science is set to shake the foundation of drug discovery and development as we know it. life sciences, biotech, pharma, CRO, drug development No (Re)programming Stem Cells for Drug Development 3 3 7 7 (Re)programming Stem Cells for Drug Development full cd19c4eb-3776-4ceb-ada6-3f354601d28e https://share.transistor.fm/s/d7d4da57 A medic by trade, Mark Kotter has always held a particular interest in neuroscience and stem cell research.

As founder and CEO of bit.bio, he's overseen the development of a unique approach to "reprogram" stem cells and change them into consistent and scalable disease-relevant cells, which can then be screened for potential therapeutics to help treat such diseases as Huntington's Alzheimer's, and ALS.

Hear about this revolutionary technology and how it works, what benefits it can provide researchers, and how it could very well shape the future of drug development.

Show Notes 

Resources 

]]> A medic by trade, Mark Kotter has always held a particular interest in neuroscience and stem cell research.

As founder and CEO of bit.bio, he's overseen the development of a unique approach to "reprogram" stem cells and change them into consistent and scalable disease-relevant cells, which can then be screened for potential therapeutics to help treat such diseases as Huntington's Alzheimer's, and ALS.

Hear about this revolutionary technology and how it works, what benefits it can provide researchers, and how it could very well shape the future of drug development.

Show Notes 

Resources 

]]> Tue, 19 Apr 2022 04:00:00 -0400 Charles River Charles River 1671 Mark Kotter, Founder and CEO of bit.bio, discusses technology to “reprogram” stem cells. Mark Kotter, Founder and CEO of bit.bio, discusses technology to “reprogram” stem cells. stem cell, stem cells, pluripotent, gene therapy, cell therapy, neuroscience, rare disease, bit.bio, life sciences, biotech, pharma, CRO, drug development No Are we One Shot Away? 3 3 6 6 Are we One Shot Away? full 74561945-c4cc-470a-9759-29a048d5d7dd https://share.transistor.fm/s/a8a04732 Imagine a gene therapy treatment that gives drug-resistant focal epilepsy patients more control over their seizures and ultimately improve their quality of life?

We sat down with Karin Agerman to discuss this possibility and discovered that her work at Combigene is at the forefront of a novel gene therapy called CG01.

Find out how this single-injection therapy is giving renewed hope to this patient population and learn more about CombiGene’s research into CG01.

SHOW NOTES

]]> Imagine a gene therapy treatment that gives drug-resistant focal epilepsy patients more control over their seizures and ultimately improve their quality of life?

We sat down with Karin Agerman to discuss this possibility and discovered that her work at Combigene is at the forefront of a novel gene therapy called CG01.

Find out how this single-injection therapy is giving renewed hope to this patient population and learn more about CombiGene’s research into CG01.

SHOW NOTES

]]> Tue, 15 Mar 2022 04:00:00 -0400 Charles River Charles River 1311 Imagine a novel gene therapy treatment that can give drug-resistant focal epilepsy patients a better quality of life. Imagine a novel gene therapy treatment that can give drug-resistant focal epilepsy patients a better quality of life. epilepsy, focal epilepsy, gene, gene therapy, neuroscience, biologic, molecule, CombiGene, CG01, life sciences, biotech, pharma, CRO, drug development No From Humble Beginnings to Potential Treatment for ALS 3 3 4 4 From Humble Beginnings to Potential Treatment for ALS full 29e93c6a-dd2b-405e-9c30-5e877e3514e0 https://share.transistor.fm/s/12bcec51 In March 2020, we invited Josh Cohen and Justin Klee on Vital Science to discuss Amylyx Pharmaceuticals, a company that had one simple mission – to improve the quality of life for those battling neurodegenerative diseases. 
 
Since their humble beginnings, what was once a company with less than ten employees has grown exponentially. Get the latest from Josh and Justin as they rejoin our podcast to discuss the new drug application process for AMX0035, what they’ve learned from their experiences, and what lies ahead. 

 

See what Amylyx Pharmaceuticals is currently working on and get updates on clinical trials.

]]> In March 2020, we invited Josh Cohen and Justin Klee on Vital Science to discuss Amylyx Pharmaceuticals, a company that had one simple mission – to improve the quality of life for those battling neurodegenerative diseases. 
 
Since their humble beginnings, what was once a company with less than ten employees has grown exponentially. Get the latest from Josh and Justin as they rejoin our podcast to discuss the new drug application process for AMX0035, what they’ve learned from their experiences, and what lies ahead. 

 

See what Amylyx Pharmaceuticals is currently working on and get updates on clinical trials.

]]> Tue, 18 Jan 2022 04:00:00 -0500 Charles River Charles River 1999 The co-founders and CEOs of Amylyx Pharmaceuticals return to discuss their latest new drug application for the treatment of ALS. The co-founders and CEOs of Amylyx Pharmaceuticals return to discuss their latest new drug application for the treatment of ALS. life sciences, biotech, pharma, CRO, drug development No Donors: The Unsung Heroes Advancing Science 3 3 3 3 Donors: The Unsung Heroes Advancing Science full 5ebd5b02-d95f-422e-aa62-2092fbdc91cd https://share.transistor.fm/s/46af6b18 The role of human cells and tissues is key in the development of next-generation therapies. With just a few samples, donors contribute to scientific advancements in medicine. This is especially true with cell and gene therapy, a field that is projected to grow over the next several years, and with it comes the growing need to find reliable and recallable donors willing to help those in need. In our latest episode of Vital Science, learn more about the critical role these unsung heroes play in advancing the future of therapeutic development.
 

Show Notes 

Resources 

]]> The role of human cells and tissues is key in the development of next-generation therapies. With just a few samples, donors contribute to scientific advancements in medicine. This is especially true with cell and gene therapy, a field that is projected to grow over the next several years, and with it comes the growing need to find reliable and recallable donors willing to help those in need. In our latest episode of Vital Science, learn more about the critical role these unsung heroes play in advancing the future of therapeutic development.
 

Show Notes 

Resources 

]]> Tue, 21 Dec 2021 04:00:00 -0500 Charles River Charles River 929 How can human cells and tissues contribute to the development of next-generation therapies? How can human cells and tissues contribute to the development of next-generation therapies? life sciences, biotech, pharma, CRO, drug development No Can MILs Strike a Killer Blow to Cancer? 3 3 2 2 Can MILs Strike a Killer Blow to Cancer? full 00f6434b-c643-4c7c-9cdc-d3d6c19c1966 https://share.transistor.fm/s/1060ad5b From a young age, Kim Noonan knew what she wanted in life — a career in science and a desire to help.

When her mother succumbed to gastric cancer, it drove her even more to help people, especially cancer patients. Today, she’s at the forefront of a potentially game-changing development in cancer therapy — using bone marrow-infiltrating lymphocytes (MILs) designed to target and kill cancerous tumors of all shapes and sizes.

Find out how her early work with myeloma patients started her road to discovering MILs, the origin of WindMIL Therapeutics, challenges associated with manufacturing MIL-based therapies, and what the future holds for this revolutionary treatment.

Learn more about WindMIL Therapeutics and the science behind their work with bone marrow immunology.

SHOW NOTES


ACKNOWLEDGMENTS

Hosted by: Gina Mullane
Narrated by: Chris Garcia
Special thanks to: Kim Noonan

]]> From a young age, Kim Noonan knew what she wanted in life — a career in science and a desire to help.

When her mother succumbed to gastric cancer, it drove her even more to help people, especially cancer patients. Today, she’s at the forefront of a potentially game-changing development in cancer therapy — using bone marrow-infiltrating lymphocytes (MILs) designed to target and kill cancerous tumors of all shapes and sizes.

Find out how her early work with myeloma patients started her road to discovering MILs, the origin of WindMIL Therapeutics, challenges associated with manufacturing MIL-based therapies, and what the future holds for this revolutionary treatment.

Learn more about WindMIL Therapeutics and the science behind their work with bone marrow immunology.

SHOW NOTES


ACKNOWLEDGMENTS

Hosted by: Gina Mullane
Narrated by: Chris Garcia
Special thanks to: Kim Noonan

]]> Tue, 19 Oct 2021 04:00:00 -0400 Charles River Charles River 1726 From a young age, Kim Noonan knew what she wanted in life — a career in science and a desire to help. When her mother succumbed to gastric cancer, it drove her even more to help people, especially cancer patients. Today, she’s at the forefront of a potentially game-changing development in cancer therapy — using bone marrow-infiltrating lymphocytes (MILs) designed to target and kill cancerous tumors of all shapes and sizes. From a young age, Kim Noonan knew what she wanted in life — a career in science and a desire to help. When her mother succumbed to gastric cancer, it drove her even more to help people, especially cancer patients. Today, she’s at the forefront of a pot life sciences, biotech, pharma, CRO, drug development No A Synergistic Approach to Treating Huntington’s Disease 3 3 1 1 A Synergistic Approach to Treating Huntington’s Disease full 23c3cd98-f884-4156-acf6-9d3687ad6207 https://share.transistor.fm/s/d15b5cfd Huntington’s disease may only affect one in every 10,000 people in the United States, but its symptoms can drastically debilitate a person’s quality of life.

For Ignacio Muñoz-Sanjuan, he witnessed first-hand the devastating effects this disease can have. He’s visited parts of the world that have the highest prevalence of Huntington’s disease on the planet, including Taiwan and South America. Today, he’s involved with two different nonprofit organizations seeking to accelerate the development of treatments to help those afflicted by, or at risk for, this fatal condition.

Join us as we explore Ignacio Muñoz-Sanjuan’s journey in raising awareness about Huntington’s disease, how Charles River contributed to developing a framework for potential treatments, and what he believes the future holds for drug development in this disease area.

Discover how the CHDI Foundation and Factor-H are working to help those suffering from Huntington’s disease and how you can get involved.

 

]]> Huntington’s disease may only affect one in every 10,000 people in the United States, but its symptoms can drastically debilitate a person’s quality of life.

For Ignacio Muñoz-Sanjuan, he witnessed first-hand the devastating effects this disease can have. He’s visited parts of the world that have the highest prevalence of Huntington’s disease on the planet, including Taiwan and South America. Today, he’s involved with two different nonprofit organizations seeking to accelerate the development of treatments to help those afflicted by, or at risk for, this fatal condition.

Join us as we explore Ignacio Muñoz-Sanjuan’s journey in raising awareness about Huntington’s disease, how Charles River contributed to developing a framework for potential treatments, and what he believes the future holds for drug development in this disease area.

Discover how the CHDI Foundation and Factor-H are working to help those suffering from Huntington’s disease and how you can get involved.

 

]]> Tue, 21 Sep 2021 04:00:00 -0400 Charles River Charles River 1943 Ignacio Muñoz-Sanjuan joins us for an in-depth look at research into Huntington’s disease. Ignacio Muñoz-Sanjuan joins us for an in-depth look at research into Huntington’s disease. Charles River, CHDI, Huntington's, Huntington's Disease, Factor-H, health, life sciences, medicine, vaccines, biotech, pharma No Opening Treatments 2 2 11 11 Opening Treatments full dc495a7e-5638-4da6-a53e-1e09f556a385 https://share.transistor.fm/s/ec9f77e4 Sanath Ramesh was determined to track down the resources needed to repurpose a drug for his son Raghav’s ultra-rare disease. This determination led him to apply his experiences and empower the rare disease community with his collaborative platform, the OpenTreatments Foundation. Find out how his repurposed drug platform is now giving hope to other rare disease patients.

EPISODE LINK

OTHER RESOURCES:  

]]> Sanath Ramesh was determined to track down the resources needed to repurpose a drug for his son Raghav’s ultra-rare disease. This determination led him to apply his experiences and empower the rare disease community with his collaborative platform, the OpenTreatments Foundation. Find out how his repurposed drug platform is now giving hope to other rare disease patients.

EPISODE LINK

OTHER RESOURCES:  

]]> Tue, 20 Jul 2021 04:00:00 -0400 Charles River Charles River 2294 One father’s quest to find a cure leads to a treatment pathway for others. One father’s quest to find a cure leads to a treatment pathway for others. Drug Repurposing, Open Treatments Foundation, Sanath Ramesh, Drug hunters, Drug development, high throughput screening, gene therapy, rare disease No Standing on the Shoulders of Giants 2 2 10 10 Standing on the Shoulders of Giants full 734c9e35-94ec-4a80-9e08-cef41ef903f5 https://share.transistor.fm/s/38a26de4 What if it was possible to speed up drug development without having to reinvent the wheel? By repurposing existing drugs, drug hunters are taking a giant step forward towards changing the future of drug discovery. Join our panel of drug hunters to hear how they reinvent previously approved drugs to get a head start towards treating patients.

Acknowledgements: 

Hosted by: Chris Garcia

Narrated by: Gina Mullane and Chris Garcia

  

Special thanks to:  

Ian Waddell
Vad Lazari
Barbara Killian

]]> What if it was possible to speed up drug development without having to reinvent the wheel? By repurposing existing drugs, drug hunters are taking a giant step forward towards changing the future of drug discovery. Join our panel of drug hunters to hear how they reinvent previously approved drugs to get a head start towards treating patients.

Acknowledgements: 

Hosted by: Chris Garcia

Narrated by: Gina Mullane and Chris Garcia

  

Special thanks to:  

Ian Waddell
Vad Lazari
Barbara Killian

]]> Tue, 15 Jun 2021 04:00:00 -0400 Charles River Charles River 1844 What if it was possible to speed up drug development without having to reinvent the wheel? By repurposing existing drugs, drug hunters are taking a giant step forward towards changing the future of drug discovery. Join our panel of drug hunters to hear how they reinvent previously approved drugs to get a head start towards treating patients. What if it was possible to speed up drug development without having to reinvent the wheel? By repurposing existing drugs, drug hunters are taking a giant step forward towards changing the future of drug discovery. Join our panel of drug hunters to hear ho Vital Science, Vital Science podcast, Charles River, Drug Repurposing, Drug Hunters, Drug Repositioning, High Throughput Screening, Rare Disease, Drug Discovery, Target Validation, Target Identification No Can a Repurposed Drug Be the Answer? 2 2 9 9 Can a Repurposed Drug Be the Answer? full d2007ad9-d1a0-4cff-a529-0a886c7c056b https://share.transistor.fm/s/2414bf1e What if the cure for your untreatable disease was just waiting on the shelf at your neighborhood pharmacy? Join physician, patient, and researcher Dr. David Fajgenbaum as he shares how his unexpected battle with Castleman disease set him on a journey to find his cure and develop new ways of using existing drugs. 

Acknowledgements: 

Hosted by: Chris Garcia

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. David Fajgenbaum
Barbara Killian

]]> What if the cure for your untreatable disease was just waiting on the shelf at your neighborhood pharmacy? Join physician, patient, and researcher Dr. David Fajgenbaum as he shares how his unexpected battle with Castleman disease set him on a journey to find his cure and develop new ways of using existing drugs. 

Acknowledgements: 

Hosted by: Chris Garcia

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. David Fajgenbaum
Barbara Killian

]]> Tue, 18 May 2021 04:00:00 -0400 Charles River Charles River 2767 Dr. David Fajgenbaum shares how repurposed drugs saved his life and their potential to save others, including COVID19 patients. Dr. David Fajgenbaum shares how repurposed drugs saved his life and their potential to save others, including COVID19 patients. vital science, vital science podcast, charles river, repurposing drugs, Dr. David Fajgenbaum, COVID19, Castelman disease, No The Life (Saving) Blood of Horseshoe Crabs 2 2 8 8 The Life (Saving) Blood of Horseshoe Crabs full 87bf096a-42d2-4000-a7ef-e1ee61d80e18 https://share.transistor.fm/s/bca2dac0 The discovery of limulus amebocyte lysate (LAL) in the blood of horseshoe crabs has forever changed bacterial endotoxin testing. Today, researchers continue to look for any way they can protect these seafaring creatures while refining testing methods to decrease the need for animals. Join our panel for an in-depth look at how they’re working with legislators to preserve the horseshoe crab population and how LAL testing is the safest in vitro method to detect harmful bacteria.   

Acknowledgements: 

Hosted by: Gina Mullane

Narrated by: Chris Garcia

  

Special thanks to:  

Dr. Norman Wainwright
Nicola Reid

]]> The discovery of limulus amebocyte lysate (LAL) in the blood of horseshoe crabs has forever changed bacterial endotoxin testing. Today, researchers continue to look for any way they can protect these seafaring creatures while refining testing methods to decrease the need for animals. Join our panel for an in-depth look at how they’re working with legislators to preserve the horseshoe crab population and how LAL testing is the safest in vitro method to detect harmful bacteria.   

Acknowledgements: 

Hosted by: Gina Mullane

Narrated by: Chris Garcia

  

Special thanks to:  

Dr. Norman Wainwright
Nicola Reid

]]> Tue, 20 Apr 2021 04:00:00 -0400 Charles River Charles River 2621 Our panel explores the vital role horseshoe crabs play in bacterial endotoxin testing and the ongoing battle to preserve the population. Our panel explores the vital role horseshoe crabs play in bacterial endotoxin testing and the ongoing battle to preserve the population. vital science, vital science podcast, charles river, horseshoe crab, sustainability, conservation, LAL, blood No 3D Cell Models: A Blueprint for Drug Development 2 2 7 7 3D Cell Models: A Blueprint for Drug Development full 20b51fcb-8623-41b9-9361-bff6d2fd7d68 https://share.transistor.fm/s/b803436c Three-dimensional cell models are primed to play a vital role in the future of drug development. By recreating tissue that mimics human systems, scientists can monitor disease progression and evaluate the effects of drug candidates. Join Drs. Elizabeth Anderson and Ian Waddell as they explain the evolution of biologic modeling and how 3D cell models are being used to develop effective therapeutics to patients. 

Acknowledgements: 

Hosted by: Gina Mullane

Narrated by: Chris Garcia

  

Special thanks to:  

Dr. Elizabeth Anderson
Dr. Ian Waddel

]]> Three-dimensional cell models are primed to play a vital role in the future of drug development. By recreating tissue that mimics human systems, scientists can monitor disease progression and evaluate the effects of drug candidates. Join Drs. Elizabeth Anderson and Ian Waddell as they explain the evolution of biologic modeling and how 3D cell models are being used to develop effective therapeutics to patients. 

Acknowledgements: 

Hosted by: Gina Mullane

Narrated by: Chris Garcia

  

Special thanks to:  

Dr. Elizabeth Anderson
Dr. Ian Waddel

]]> Tue, 16 Mar 2021 04:00:00 -0400 Charles River Charles River 1738 How are 3D cell models changing our ability to create more effective therapies? Our panel of scientific experts discuss. How are 3D cell models changing our ability to create more effective therapies? Our panel of scientific experts discuss. vital science, vital science podcast, charles river, 3D Models, Drug Development, Drug Candidates, In Vitro 3D Models No Driving Drug Development with CRISPR/Cas9 2 2 6 6 Driving Drug Development with CRISPR/Cas9 full 3d97c000-e9ec-409c-8f4a-6f6a3b731807 https://share.transistor.fm/s/666060b8 Within the past decade, CRISPR/Cas9 gene editing of mammalian cells has become common practice, but does it hold the key to unlocking future of therapeutic development? Join Dr. David Fischer and our panel for a detailed look at the advantages and applications of this Nobel Prize-winning technology.   

Acknowledgements: 

Hosted by: Gina Mullane

Narrated by: Chris Garcia

  

Special thanks to:  

Dr. David Fischer

]]> Within the past decade, CRISPR/Cas9 gene editing of mammalian cells has become common practice, but does it hold the key to unlocking future of therapeutic development? Join Dr. David Fischer and our panel for a detailed look at the advantages and applications of this Nobel Prize-winning technology.   

Acknowledgements: 

Hosted by: Gina Mullane

Narrated by: Chris Garcia

  

Special thanks to:  

Dr. David Fischer

]]> Tue, 16 Feb 2021 04:00:00 -0500 Charles River Charles River 1597 Dr. David Fischer joins our panel to discuss the evolution, application, and potential of CRISPR/Cas9 gene editing technology. Dr. David Fischer joins our panel to discuss the evolution, application, and potential of CRISPR/Cas9 gene editing technology. vital science, vital science podcast, charles river, crispr, crispr/cas9, david fischer No Get the Series Recap: Vaccines 2 2 5 5 Get the Series Recap: Vaccines full 9390d3f5-fb0c-49b2-9b23-eff33d530f43 https://share.transistor.fm/s/4ff952d0 Get your four-part dose of vaccine…information, that is. In this brief recap, Vital Science hosts Gina Mullane and Chris Garcia chat about the content of our first several Season 2 episodes – a miniseries covering infectious disease and immunity, origins of vaccination, therapeutic development and regulation, and the scientific community’s recent accomplishments in the fight against COVID. 

Download individual episodes:  

See what you might have missed in the vaccine series or download and save individual episodes on our Season 2 tab.  

 

Beyond the podcast:  

Season 1 of Vital Science™ shared numerous compelling stories, like that of the Hermstad twins and their battle with ALS (Episode 7, An Uncommon Bond). Sadly, Jaci passed away shortly after her podcast aired, but the fight continues as clinicians, advocates, and drug developers continue to work in her honor. As Chris mentions in the recap, if you’re interested in the next chapter of her story, you won’t want to miss a free virtual event with our special guests Ben Stiller and Project ALS:  

 

The Hermstad Legacy: Advances in Treatment for ALS 

A Rare Disease Trailblazer Event 

Thursday, February 4 | 11 a.m. – 4:00 p.m. ET

Register 

Acknowledgements: 

Hosted by: Gina Mullane and Chris Garcia

]]> Get your four-part dose of vaccine…information, that is. In this brief recap, Vital Science hosts Gina Mullane and Chris Garcia chat about the content of our first several Season 2 episodes – a miniseries covering infectious disease and immunity, origins of vaccination, therapeutic development and regulation, and the scientific community’s recent accomplishments in the fight against COVID. 

Download individual episodes:  

See what you might have missed in the vaccine series or download and save individual episodes on our Season 2 tab.  

 

Beyond the podcast:  

Season 1 of Vital Science™ shared numerous compelling stories, like that of the Hermstad twins and their battle with ALS (Episode 7, An Uncommon Bond). Sadly, Jaci passed away shortly after her podcast aired, but the fight continues as clinicians, advocates, and drug developers continue to work in her honor. As Chris mentions in the recap, if you’re interested in the next chapter of her story, you won’t want to miss a free virtual event with our special guests Ben Stiller and Project ALS:  

 

The Hermstad Legacy: Advances in Treatment for ALS 

A Rare Disease Trailblazer Event 

Thursday, February 4 | 11 a.m. – 4:00 p.m. ET

Register 

Acknowledgements: 

Hosted by: Gina Mullane and Chris Garcia

]]> Tue, 19 Jan 2021 04:00:00 -0500 Charles River Charles River 200 In this brief recap, our hosts Gina Mullane and Chris Garcia discuss topics covered in our series on vaccines. In this brief recap, our hosts Gina Mullane and Chris Garcia discuss topics covered in our series on vaccines. vital science, vital science podcast, charles river, vaccine, vaccine development, coivd-19, recap, series recap, series, gina mullane, chris garcia No COVID-19 Vaccines – Behind the Scenes 2 2 4 4 COVID-19 Vaccines – Behind the Scenes full ca8f5350-1868-49b7-bf3e-5b11a3e65b0a https://share.transistor.fm/s/8c7dc0f6 Recent developments in the race to develop a COVID vaccine show promise, but the question remains – when will it become available to the general public? Dr. Sarah Gould returns for the fourth and final installment of our vaccine miniseries to examine where we stand with the development of COVID-19 vaccines and some lingering challenges that may hamper their final approval.     

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Sarah Gould

]]> Recent developments in the race to develop a COVID vaccine show promise, but the question remains – when will it become available to the general public? Dr. Sarah Gould returns for the fourth and final installment of our vaccine miniseries to examine where we stand with the development of COVID-19 vaccines and some lingering challenges that may hamper their final approval.     

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Sarah Gould

]]> Tue, 15 Dec 2020 04:00:00 -0500 Charles River Charles River 1229 Dr. Sarah Gould returns to provide an update on the development of a vaccine for COVID-19 and what lies ahead. Dr. Sarah Gould returns to provide an update on the development of a vaccine for COVID-19 and what lies ahead. vital science, vital science podcast, charles river, vaccine, vaccine development, coivd-19, sarah gould No Beyond the Headlines: Understanding Accelerated Vaccines 2 2 3 3 Beyond the Headlines: Understanding Accelerated Vaccines full 1400952e-e637-4370-af59-f9595a3f930e https://share.transistor.fm/s/ed27fc9f “Accelerating” a vaccine for COVID-19 has piqued the interest of many, but is it really possible to develop one quickly and safely? Join distinguished scientist Dr. Lauren Black as she dives into the typical mechanisms behind a vaccine and why it takes several years to deliver one safely to the general public. 

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Lauren Black

]]> “Accelerating” a vaccine for COVID-19 has piqued the interest of many, but is it really possible to develop one quickly and safely? Join distinguished scientist Dr. Lauren Black as she dives into the typical mechanisms behind a vaccine and why it takes several years to deliver one safely to the general public. 

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Lauren Black

]]> Tue, 17 Nov 2020 04:00:00 -0500 Charles River Charles River 1391 Distinguished scientist Dr. Lauren Black discusses a “weight-of-evidence” approach to accelerated vaccine development and approvals. Distinguished scientist Dr. Lauren Black discusses a “weight-of-evidence” approach to accelerated vaccine development and approvals. vital science, charles river, vital science podcast, infectious disease, vaccine, vaccines, COVID-19, lauren black, accelerated, development, distinguished scientist No A Formidable Defense Against Infectious Diseases  2 2 2 2 A Formidable Defense Against Infectious Diseases  full 9b235f73-4854-4fd6-bef1-c3df2be04c53 https://share.transistor.fm/s/79dfef8c When the immune system is compromised, people rely on vaccines to eliminate and inactivate the threat. However, the process with which this happens is anything but simple. Dr. Christina Satterwhite joins us to explain how the immune system works and how vaccines target harmful pathogens in the second installment of our series on vaccines.

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Christina Satterwhite

]]> When the immune system is compromised, people rely on vaccines to eliminate and inactivate the threat. However, the process with which this happens is anything but simple. Dr. Christina Satterwhite joins us to explain how the immune system works and how vaccines target harmful pathogens in the second installment of our series on vaccines.

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Christina Satterwhite

]]> Tue, 20 Oct 2020 04:00:00 -0400 Charles River Charles River 2804 Dr. Christina Satterwhite delves into the immune system and how vaccines target harmful pathogens.  Dr. Christina Satterwhite delves into the immune system and how vaccines target harmful pathogens.  vital science, charles river, vital science podcast, infectious disease, vaccine, vaccines, immune system, pathogens, COVID-19 No Infectious Disease and The Rise of Vaccines 2 2 1 1 Infectious Disease and The Rise of Vaccines full ab444c8a-4541-459d-9f26-e7e40609992a https://share.transistor.fm/s/8cb8a336 Since 1796, vaccines have helped humans combat smallpox, the flu, and other infectious diseases. The process of vaccine development has changed drastically since then, and is now front and center in the wake of COVID-19. In the first episode of our series on vaccines, join us as we talk with Dr. Sarah Gould about the history of vaccines and infectious disease.   

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Sarah Gould

]]> Since 1796, vaccines have helped humans combat smallpox, the flu, and other infectious diseases. The process of vaccine development has changed drastically since then, and is now front and center in the wake of COVID-19. In the first episode of our series on vaccines, join us as we talk with Dr. Sarah Gould about the history of vaccines and infectious disease.   

Acknowledgements: 

Hosted by: Chris Garcia 

Narrated by: Gina Mullane

  

Special thanks to:  

Dr. Sarah Gould

]]> Tue, 22 Sep 2020 04:00:00 -0400 Charles River Charles River 1180 Dr. Sarah Gould explains how infectious disease spurred the discovery and subsequent evolution of vaccines. Dr. Sarah Gould explains how infectious disease spurred the discovery and subsequent evolution of vaccines. vital science, charles river, vital science podcast, infectious disease, vaccine, vaccines, infectious diseases, COVID-19 No Two in the Same 1 1 10 10 Two in the Same full ffcb1302-3e9f-4306-b8b5-9aa8c5abd232 https://share.transistor.fm/s/6cebab6a Cate and Laura Cheevers are sisters who were both born with cystic fibrosis. Together, they’ve been through multiple clinical trials for genotype-specific treatments and continue to defy the odds. Hear their unique tales of growing up with this rare genetic disorder and how it’s shaped their lives today. 

Learn more about how the Cystic Fibrosis Foundation and Vertex Pharmaceuticals are working on treatments to aid those living with CF, and support Great Strides on their quest to find a cure for CF. 

Acknowledgements: 

Hosted by: Chris Garcia 

Produced and Edited by: Meaghan Root and Ryan Stevenson 

Sound and Music by: Ryan Stevenson 

  

Special thanks to:  

Kim, Cate, and Laura Cheevers 

]]> Cate and Laura Cheevers are sisters who were both born with cystic fibrosis. Together, they’ve been through multiple clinical trials for genotype-specific treatments and continue to defy the odds. Hear their unique tales of growing up with this rare genetic disorder and how it’s shaped their lives today. 

Learn more about how the Cystic Fibrosis Foundation and Vertex Pharmaceuticals are working on treatments to aid those living with CF, and support Great Strides on their quest to find a cure for CF. 

Acknowledgements: 

Hosted by: Chris Garcia 

Produced and Edited by: Meaghan Root and Ryan Stevenson 

Sound and Music by: Ryan Stevenson 

  

Special thanks to:  

Kim, Cate, and Laura Cheevers 

]]> Tue, 21 Jul 2020 04:00:00 -0400 Charles River Charles River 2492 Two sisters share their experience with clinical trials for cystic fibrosis. Two sisters share their experience with clinical trials for cystic fibrosis. vital science, charles river, rare disease, cystic fibrosis, vertex, vital science podcast No New Lease on Life 1 1 9 9 New Lease on Life full 229ff932-0752-465b-96c7-34f3c8ce7972 https://share.transistor.fm/s/f2da0bd0 Dr. Guy Leclerc plays the role of both a researcher and a clinician, changing lives with his work on medical devices. Learn how his work directly improved the quality of life for a very special patient.

Learn more about Isabelle’s story, and support what drives Dr. Leclerc by donating to the CHUM foundation.

ACKNOWLEDGMENTS
Hosted by: Gina Mullane
Produced and Edited by: Meaghan Root and Ryan Stevenson
Sound and Music by: David Coscia and Ryan Stevenson
Special thanks to: Dr. Guy Leclerc, Isabelle

]]> Dr. Guy Leclerc plays the role of both a researcher and a clinician, changing lives with his work on medical devices. Learn how his work directly improved the quality of life for a very special patient.

Learn more about Isabelle’s story, and support what drives Dr. Leclerc by donating to the CHUM foundation.

ACKNOWLEDGMENTS
Hosted by: Gina Mullane
Produced and Edited by: Meaghan Root and Ryan Stevenson
Sound and Music by: David Coscia and Ryan Stevenson
Special thanks to: Dr. Guy Leclerc, Isabelle

]]> Tue, 16 Jun 2020 04:00:00 -0400 Charles River Charles River 2078 A dual role in medical device gives hope to one unique patient. A dual role in medical device gives hope to one unique patient. vital science, charles river, medical device, guy leclerc, vital science podcast No Leading the Way 1 1 8 8 Leading the Way full 764c30b0-4154-42bb-a30f-cfa0cb6ccdd8 https://share.transistor.fm/s/895856c3 Jake Glanville, founding partner and CEO of Distributed Bio, has been featured in the Netflix series "Pandemic." Now, he and his team are on the front lines of the fight against COVID-19, working tirelessly to find a cure.

Learn how his roots in Guatemala have shaped his beliefs on healthcare, how a family business has developed his skills as a leader, and how it all came together in his leadership of a talented, accomplished team of scientists.

Read more about antibody discovery technologies and advancements.

ACKNOWLEDGMENTS

Hosted by: Gina Mullane
Produced and Edited by: Meaghan Root, Ryan Stevenson, and Pam Williams
Sound and Music by: David Coscia and Ryan Stevenson

Special thanks to: Jacob Glanville, PhD

]]> Jake Glanville, founding partner and CEO of Distributed Bio, has been featured in the Netflix series "Pandemic." Now, he and his team are on the front lines of the fight against COVID-19, working tirelessly to find a cure.

Learn how his roots in Guatemala have shaped his beliefs on healthcare, how a family business has developed his skills as a leader, and how it all came together in his leadership of a talented, accomplished team of scientists.

Read more about antibody discovery technologies and advancements.

ACKNOWLEDGMENTS

Hosted by: Gina Mullane
Produced and Edited by: Meaghan Root, Ryan Stevenson, and Pam Williams
Sound and Music by: David Coscia and Ryan Stevenson

Special thanks to: Jacob Glanville, PhD

]]> Fri, 15 May 2020 18:30:00 -0400 Charles River Charles River 1814 Jake Glanville talks leadership and the COVID-19 fight. Jake Glanville talks leadership and the COVID-19 fight. covid-19, jake glanville, distributed bio, covid No Uncommon Bond 1 1 7 7 Uncommon Bond full 913df98b-70d0-4e9c-b355-d5989762fff3 https://share.transistor.fm/s/d959989b Twins share many unique bonds, and for Jaci and Alex, fighting the same rare disease is one of them. Hear this emotional tale through the perspective of their mom, Lori, and their uncle, Mike, about how they have battled their illness, knowing the risks, and helped to develop a new treatment for this rare form of ALS.

To learn more about Jaci’s story, please visit Cowgirl Up for Jaci: Roping in a CURE for ALS. For more information about ALS, please visit Project ALS.

ACKNOWLEDGMENTS

Hosted by: Chris Garcia
Produced by: Meaghan Root, Ryan Stevenson, and Laura Robinson
Sound and Music by: Ryan Stevenson

Special thanks to: Lori Hermstad, and Mike Hadden
In memoriam: Jaci Hermstad and Alex Hermstad

]]> Twins share many unique bonds, and for Jaci and Alex, fighting the same rare disease is one of them. Hear this emotional tale through the perspective of their mom, Lori, and their uncle, Mike, about how they have battled their illness, knowing the risks, and helped to develop a new treatment for this rare form of ALS.

To learn more about Jaci’s story, please visit Cowgirl Up for Jaci: Roping in a CURE for ALS. For more information about ALS, please visit Project ALS.

ACKNOWLEDGMENTS

Hosted by: Chris Garcia
Produced by: Meaghan Root, Ryan Stevenson, and Laura Robinson
Sound and Music by: Ryan Stevenson

Special thanks to: Lori Hermstad, and Mike Hadden
In memoriam: Jaci Hermstad and Alex Hermstad

]]> Tue, 21 Apr 2020 04:00:00 -0400 Charles River Charles River 2779 Twins are forever connected in their fight against a rare disease. Twins are forever connected in their fight against a rare disease. vital science, vital science podcast, episode 07, rare disease, ALS, charles river, charles river podcast No Humble Beginnings 1 1 6 6 Humble Beginnings full 34bb555c-103b-4bb0-9f45-ae0d59cd4ed6 https://share.transistor.fm/s/106fe812 College can take you many places. In the case of two neuroscience students, they didn’t know where their journey would take them. Their perseverance and fighting spirit built a company that aims to help those battling neurodegenerative diseases.

See what Amylyx is working on.

]]> College can take you many places. In the case of two neuroscience students, they didn’t know where their journey would take them. Their perseverance and fighting spirit built a company that aims to help those battling neurodegenerative diseases.

See what Amylyx is working on.

]]> Tue, 17 Mar 2020 04:00:00 -0400 Charles River Charles River 2174 Two students, a dorm room, and a “crazy idea” to help patients. Two students, a dorm room, and a “crazy idea” to help patients. charles river, crl, vital science, amylyx, als, alzheimer's No An Angel’s Determination 1 1 5 5 An Angel’s Determination full 3ed7723c-50cb-44dc-b4ee-5f942871b67e https://share.transistor.fm/s/8a0474f7 There are certain moments when life takes on a whole new meaning. For Allyson Berent, her daughter’s diagnosis with a rare genetic disorder gave her a purpose – to embark on the quest for a cure. Hear her remarkable journey from a veterinarian to the COO of GeneTx Biotherapeutics, and how partnering with Ultragenyx pharmaceutical fuels her determination to cure Angelman Syndrome.

Learn more about FAST (Foundation for Angelman Syndrome Therapeutics).  

]]> There are certain moments when life takes on a whole new meaning. For Allyson Berent, her daughter’s diagnosis with a rare genetic disorder gave her a purpose – to embark on the quest for a cure. Hear her remarkable journey from a veterinarian to the COO of GeneTx Biotherapeutics, and how partnering with Ultragenyx pharmaceutical fuels her determination to cure Angelman Syndrome.

Learn more about FAST (Foundation for Angelman Syndrome Therapeutics).  

]]> Sat, 15 Feb 2020 09:30:00 -0500 Charles River Charles River 3166 A personal transformation from veterinarian to rare disease advocate. A personal transformation from veterinarian to rare disease advocate. vital science podcast, rare disease, angelman syndrome, allyson berent No Turning Point 1 1 4 4 Turning Point full 874cd37a-89ef-42ce-ad5e-b9aa67c0b748 https://share.transistor.fm/s/8fe9a2f1 What we experience can leave a lasting impact on our lives. In Carina’s case, her father’s diagnosis changed her career forever. Hear the emotional story of her ongoing fight to honor his memory and help others battling this rare neurodegenerative disease.

Learn more about the Multiple System Atrophy Coalition

]]> What we experience can leave a lasting impact on our lives. In Carina’s case, her father’s diagnosis changed her career forever. Hear the emotional story of her ongoing fight to honor his memory and help others battling this rare neurodegenerative disease.

Learn more about the Multiple System Atrophy Coalition

]]> Tue, 21 Jan 2020 04:00:00 -0500 Charles River Charles River 1736 How an unexpected challenge changed one employee's career path forever. How an unexpected challenge changed one employee's career path forever. cns, rare disease, vital science, charles river, charles river podcast, msa, multiple system atrophy No A Toxigenic Situation 1 1 3 3 A Toxigenic Situation full 35cb68bb-0c47-4bf1-b1c1-d46994aca414 https://share.transistor.fm/s/340f9c18 Donnie Patterson is not just a pharmaceutical microbiologist. He’s also a victim of toxigenic mold, a growing problem in South Carolina schools. Hear how his story exposed an issue that led to his ongoing fight for tougher mold testing regulations.

Visit the Global Indoor Health Network website for more information on toxic mold.

]]> Donnie Patterson is not just a pharmaceutical microbiologist. He’s also a victim of toxigenic mold, a growing problem in South Carolina schools. Hear how his story exposed an issue that led to his ongoing fight for tougher mold testing regulations.

Visit the Global Indoor Health Network website for more information on toxic mold.

]]> Tue, 17 Dec 2019 03:45:00 -0500 Charles River Charles River 2469 A microbiologist affected by mold fights for children’s health in South Carolina. A microbiologist affected by mold fights for children’s health in South Carolina. charles river podcast, toxigenic mold, mold No The Pathway 1 1 2 2 The Pathway full 7ea885ef-88ac-4e79-81b5-7282232ffa20 https://share.transistor.fm/s/619dc84d Mila’s groundbreaking treatment, the first created and approved for a single patient, has given hope to thousands of rare-disease patients around the world. Hear Julia Vitarello, Mila’s Mom, and Dr. Timothy Yu discuss their plans to help other children with rare disease.

Watch the documentary and learn more about Mila’s story at: www.criver.com/everystep

In partnership with Mila’s Miracle Foundation, we are on a mission to bring this new treatment path to children fighting rare diseases. An anonymous donor will match up to $150,000 in donations to help with this fight, and Charles River has already donated $50,000 to get the campaign started.

Join our giving campaign

ACKNOWLEDGMENTS

Hosted by: Gina Mullane and Chris Garcia
Produced by: Meaghan Root and Ryan Stevenson
Sound and Music by: Ryan Stevenson

Special thanks to: Julia Vitarello, Dr. Timothy Yu, and Boston Children’s Hospital.

]]> Mila’s groundbreaking treatment, the first created and approved for a single patient, has given hope to thousands of rare-disease patients around the world. Hear Julia Vitarello, Mila’s Mom, and Dr. Timothy Yu discuss their plans to help other children with rare disease.

Watch the documentary and learn more about Mila’s story at: www.criver.com/everystep

In partnership with Mila’s Miracle Foundation, we are on a mission to bring this new treatment path to children fighting rare diseases. An anonymous donor will match up to $150,000 in donations to help with this fight, and Charles River has already donated $50,000 to get the campaign started.

Join our giving campaign

ACKNOWLEDGMENTS

Hosted by: Gina Mullane and Chris Garcia
Produced by: Meaghan Root and Ryan Stevenson
Sound and Music by: Ryan Stevenson

Special thanks to: Julia Vitarello, Dr. Timothy Yu, and Boston Children’s Hospital.

]]> Tue, 19 Nov 2019 03:15:00 -0500 Charles River Charles River 2914 Mila’s story for customized medicine paves the way for other children. Mila’s story for customized medicine paves the way for other children. charles river, charles river labs, vital science, batten's disease, rare disease No Being the First 1 1 1 1 Being the First full 93ba1603-c01f-4481-9ed4-bd51311cb763 https://share.transistor.fm/s/80c9ea9e Mila is a young girl fighting Batten Disease, a rare, fatal disease with no cure. Her Mom, Julia Vitarello sits down with Gina to tell the story of Mila’s diagnosis and her incredible journey since; from diagnosis to Mila’s experimental genetic treatment, created just for her.

Watch the documentary and learn more about Mila’s story at www.criver.com/everystep.

Hosted by: Gina Mullane and Chris Garcia
Produced by: Meaghan Root, Ryan Stevenson
Sound and Music by: Ryan Stevenson
Special thanks to: Julia Vitarello, Dr. Timothy Yu, and Boston Children’s Hospital. 

]]> Mila is a young girl fighting Batten Disease, a rare, fatal disease with no cure. Her Mom, Julia Vitarello sits down with Gina to tell the story of Mila’s diagnosis and her incredible journey since; from diagnosis to Mila’s experimental genetic treatment, created just for her.

Watch the documentary and learn more about Mila’s story at www.criver.com/everystep.

Hosted by: Gina Mullane and Chris Garcia
Produced by: Meaghan Root, Ryan Stevenson
Sound and Music by: Ryan Stevenson
Special thanks to: Julia Vitarello, Dr. Timothy Yu, and Boston Children’s Hospital. 

]]> Tue, 22 Oct 2019 03:15:00 -0400 Charles River Charles River 2636 From diagnosis to experimental genetic treatment, this is Mila's story. From diagnosis to experimental genetic treatment, this is Mila's story. charles river, drug discovery, life science, science, pharma, batten's disease, rare disease No This is Vital Science™ 1 1 This is Vital Science™ trailer d3f85370-dda5-4d2f-9dd1-9fbe228b8542 https://share.transistor.fm/s/cca1ba60 Meet our hosts Gina Mullane and Chris Garcia as they introduce Vital Science™, a brand new podcast that shares the personal stories of those impacted by life science. Subscribe so you don't miss us, starting October 2019.

ACKNOWLEDGMENTS

Hosted by: Gina Mullane and Chris Garcia
Produced by: Meaghan Root and Ryan Stevenson
Sound and Music by: Ryan Stevenson

]]> Meet our hosts Gina Mullane and Chris Garcia as they introduce Vital Science™, a brand new podcast that shares the personal stories of those impacted by life science. Subscribe so you don't miss us, starting October 2019.

ACKNOWLEDGMENTS

Hosted by: Gina Mullane and Chris Garcia
Produced by: Meaghan Root and Ryan Stevenson
Sound and Music by: Ryan Stevenson

]]> Thu, 26 Sep 2019 17:00:00 -0400 Charles River Charles River 72 Join us as we explore the motivation and personal connection to the life sciences. Join us as we explore the motivation and personal connection to the life sciences. charles river, drug discovery, life science, science, pharma No